2017 European League Against Rheumatism/American C classification criteria for adult and juvenile idiopathic in major subgroups

Annals of the Rheumatic Diseases

76, 1955-1964

DOI: 10.1136/annrheumdis-2017-211468

Citation Report

#	Article	IF	Citations
1	EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report. RMD Open, 2017, 3, e000507.	1.8	115
2	Consideration of Antisynthetase Syndrome Features in Classifying Patients as Having Idiopathic Inflammatory Myopathy: Comment on the Article by Lundberg et al. Arthritis and Rheumatology, 2018, 70, 975-976.	2.9	6
3	Current diagnosis and treatment of polymyositis and dermatomyositis. Modern Rheumatology, 2018, 28, 913-921.	0.9	82
4	Gastrointestinal Tract Vasculopathy. American Journal of Surgical Pathology, 2018, 42, 866-876.	2.1	46
5	Dermatomyositis Clinical and Pathological Phenotypes Associated with Myositis-Specific Autoantibodies. Current Rheumatology Reports, 2018, 20, 28.	2.1	76
6	Classification of myositis. Nature Reviews Rheumatology, 2018, 14, 269-278.	3.5	210
7	Applicability of EULAR/ACR classification criteria for dermatomyositis to amyopathic disease. Journal of the American Academy of Dermatology, 2018, 79, 77-83.e1.	0.6	42
8	Response to: â€˜Performance of the 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies in clinical practiceâ€™ by HoÄevar et al. Annals of the Rheumatic Diseases, 2018, 77, e91-e91.	0.5	43
9	Bench to bedside review of myositis autoantibodies. Clinical and Molecular Allergy, 2018, 16, 5.	0.8	59
10	New Myositis Classification Criteriaâ€”What We Have Learned Since Bohan and Peter. Current Rheumatology Reports, 2018, 20, 18.	2.1	65
11	2017 EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: little emphasis on autoantibodies, why?. Annals of the Rheumatic Diseases, 2018, 77, e77-e77.	0.5	23
12	Response to: '2017 EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: little emphasis on autoantibodies, why?' by Malaviya. Annals of the Rheumatic Diseases, 2018, 77, e78-e78.	0.5	19
13	Performance of the 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies in clinical practice. Annals of the Rheumatic Diseases, 2018, 77, e90-e90.	0.5	14
14	Myositis in clinical practiceâ€”relevance of new antibodies. Best Practice and Research in Clinical Rheumatology, 2018, 32, 887-901.	1.4	3
15	OP0147â€…Aberrant activation of type i interferon system in anti-mda5 dermatomyositis patients. , 2018, , .		0
16	Myositis an evolving spectrum of disease. Immunological Medicine, 2018, 41, 46-54.	1.4	14
18	Increasing incidence of adult idiopathic inflammatory myopathies in the City of Salford, UK: a 10-year epidemiological study. Rheumatology Advances in Practice, 2018, 2, rky035.	0.3	15
19	Current Treatment for Myositis. Current Treatment Options in Rheumatology, 2018, 4, 299-315.	0.6	36

#	Article	IF	Citations
20	Systemic and Tissue Inflammation in Juvenile Dermatomyositis: From Pathogenesis to the Quest for Monitoring Tools. Frontiers in Immunology, 2018, 9, 2951.	2.2	50
21	Utility of [18F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Scan in Inflammatory Myopathies: Case Report and Literature Review. Case Reports in Rheumatology, 2018, 2018, 1-5.	0.2	1
22	Patients with anti-Jo1 antibodies display a characteristic IgG Fc-glycan profile which is further enhanced in anti-Jo1 autoantibodies. Scientific Reports, 2018, 8, 17958.	1.6	12
23	MiopatÃas inflamatorias. Revista MÃ©dica ClÃnica Las Condes, 2018, 29, 611-621.	0.2	2
25	Proximal muscle weakness and skin rash. BMJ: British Medical Journal, 2018, 363, k3614.	2.4	0
26	New insights in myositis-specific autoantibodies. Current Opinion in Rheumatology, 2018, 30, 614-622.	2.0	37
28	Autoimmune Myopathies: Updates on Evaluation and Treatment. Neurotherapeutics, 2018, 15, 976-994.	2.1	55
29	The diagnostic work-up of cancer-associated myositis. Current Opinion in Rheumatology, 2018, 30, 630-636.	2.0	37
30	T-cell transcriptomics from peripheral blood highlights differences between polymyositis and dermatomyositis patients. Arthritis Research and Therapy, 2018, 20, 188.	1.6	21
31	Recent developments in classification criteria and diagnosis guidelines for idiopathic inflammatory myopathies. Current Opinion in Rheumatology, 2018, 30, 606-613.	2.0	17
32	Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status. Annals of the Rheumatic Diseases, 2018, 77, 1432-1439.	0.5	79
33	Current Classification and Management of Inflammatory Myopathies. Journal of Neuromuscular Diseases, 2018, 5, 109-129.	1.1	190
34	Interstitial Pneumonia With Autoimmune Features. Arthritis and Rheumatology, 2018, 70, 1901-1913.	2.9	38
35	Long-term follow-up of nailfold videocapillaroscopic changes in dermatomyositis versus systemic sclerosis patients. Clinical Rheumatology, 2018, 37, 2723-2729.	1.0	14
36	Targeted lipidomics analysis identified altered serum lipid profiles in patients with polymyositis and dermatomyositis. Arthritis Research and Therapy, 2018, 20, 83.	1.6	22
37	Classification and management of adult inflammatory myopathies. Lancet Neurology, The, 2018, 17, 816-828.	4.9	267
38	Expression of interleukin-18 in muscle tissue of patients with polymyositis or dermatomyositis and effects of conventional immunosuppressive treatment. Rheumatology, 2018, 57, 2149-2157.	0.9	13
39	Muscle pain syndromes and fibromyalgia: the role of muscle biopsy. Current Opinion in Supportive and Palliative Care, 2018, 12, 382-387.	0.5	17

#	Article	IF	Citations
40	The incidence of idiopathic inflammatory myopathies in the adult Slovenian population. Clinical Rheumatology, 2019, 38, 279-283.	1.0	3
41	Myositis autoantibody profiles and their clinical associations in Greek patients with inflammatory myopathies. Clinical Rheumatology, 2019, 38, 125-132.	1.0	35
42	Response to: â€˜Time to personalise the treatment of anti-MDA-5 associated lung diseaseâ€™ by Lake et al. Annals of the Rheumatic Diseases, 2019, 78, e53-e53.	0.5	1
44	Including myositis-specific autoantibodies improves performance of the idiopathic inflammatory myopathies classification criteria. Rheumatology, 2019, 58, 2331-2333.	0.9	4
45	Imaging of Inflammatory Myopathies. , 2019, , 2185-2197.		0
46	Effectiveness of Tai Chi on fibromyalgia patients: A meta-analysis of randomized controlled trials. Complementary Therapies in Medicine, 2019, 46, 1-8.	1.3	35
47	Dysphagia as Isolated Manifestation of Jo-1 Associated Myositis?. Frontiers in Neurology, 2019, 10, 739.	1.1	11
48	Undifferentiated connective tissue disease: state of the art on clinical practice guidelines. RMD Open, 2019, 4, e000786.	1.8	28
49	Comment on: Muscle fluorodeoxyglucose uptake assessed by positron emission tomography-computed tomography as a biomarker of inflammatory myopathies disease activity: reply. Rheumatology, 2019, 58, 2345-2346.	0.9	3
50	Idiopathic and immuneâ€related pulmonary fibrosis: diagnostic and therapeutic challenges. Clinical and Translational Immunology, 2019, 8, e1086.	1.7	22
51	Demographic and clinical predictors of progression and mortality in connective tissue disease-associated interstitial lung disease: a retrospective cohort study. BMC Pulmonary Medicine, 2019, 19, 192.	0.8	37
52	The Role of the Multidisciplinary Evaluation of Interstitial Lung Diseases: Systematic Literature Review of the Current Evidence and Future Perspectives. Frontiers in Medicine, 2019, 6, 246.	1.2	59
53	Idiopathic Inflammatory Myopathies. Rheumatic Disease Clinics of North America, 2019, 45, 569-581.	0.8	41
54	Comment on: Muscle fluorodeoxyglucose uptake assessed by positron emission tomography-computed tomography as a biomarker of inflammatory myopathies disease activity. Rheumatology, 2019, 58, 2344-2345.	0.9	0
55	Evaluation of a novel particle-based assay for detection of autoantibodies in idiopathic inflammatory myopathies. Journal of Immunological Methods, 2019, 474, 112661.	0.6	18
56	Clinical Applications of Synovial Biopsy. Frontiers in Medicine, 2019, 6, 102.	1.2	5
57	Tertiary lymphoid organs in the inflammatory myopathy associated with PD-1 inhibitors. , 2019, 7, 256.		13
58	Development and validation of a composite disease activity score for measurement of muscle and skin involvement in juvenile dermatomyositis. Rheumatology, 2019, 58, 1196-1205.	0.9	10

#	Article	IF	Citations
59	Efficacy and safety of rituximab in anti-synthetase antibody positive and negative subjects with idiopathic inflammatory myopathy: a registry-based study. Rheumatology, 2019, 58, 1214-1220.	0.9	22
60	Imaging in the diagnosis of idiopathic inflammatory myopathies; indications and utility. Expert Review of Neurotherapeutics, 2019, 19, 173-184.	1.4	7
61	Anti-Ku syndrome with elevated CK and anti-Ku syndrome with anti-dsDNA are two distinct entities with different outcomes. Annals of the Rheumatic Diseases, 2019, 78, 1101-1106.	0.5	54
62	Biomarkers in Inflammatory Myopathiesâ€"An Expanded Definition. Frontiers in Neurology, 2019, 10, 554.	1.1	48
63	Validation of 2017 classification criteria for adult and juvenile idiopathic inflammatory myopathies proposed by EULAR/ACR in Chinese patients. International Journal of Rheumatic Diseases, 2019, 22, 1278-1282.	0.9	15
64	An Anti-PM/Scl-75 Antibody-positive Japanese Woman Who Developed Inflammatory Myopathy. Internal Medicine, 2019, 58, 2689-2693.	0.3	4
66	Idiopathic inflammatory myopathy comorbid with Sturge-Weber syndrome: a case report. BMC Neurology, 2019, 19, 87.	0.8	1
67	Comparison of Three Immunoassays for the Detection of Myositis Specific Antibodies. Frontiers in Immunology, 2019, 10, 848.	2.2	54
68	Comparison of the 2017 EULAR/ACR criteria with Bohan and Peter criteria for the classification of idiopathic inflammatory myopathies. Clinical Rheumatology, 2019, 38, 1931-1934.	1.0	18
69	Successful treatment of extensive calcifications and acute pulmonary involvement in dermatomyositis with the Janus-Kinase inhibitor tofacitinib â€" A report of two cases. Journal of Autoimmunity, 2019, 100, 131-136.	3.0	78
70	The IgG2 Isotype of Antiâ€"Transcription Intermediary Factor 1Î³ Autoantibodies Is a Biomarker of Cancer and Mortality in Adult Dermatomyositis. Arthritis and Rheumatology, 2019, 71, 1360-1370.	2.9	33
71	Strategy for suspected myositis. Joint Bone Spine, 2019, 86, 568-575.	0.8	3
72	Autoantibody testing in idiopathic inflammatory myopathies. Practical Neurology, 2019, 19, 284-294.	0.5	16
73	Imaging of Inflammatory Myopathies. , 2019, , 1-13.		0
74	Idiopathic inflammatory myopathies and antisynthetase syndrome: contribution of antisynthetase antibodies to improve current classification criteria. Annals of the Rheumatic Diseases, 2019, 78, 1291-1292.	0.5	16
75	Muscle fluorodeoxyglucose uptake assessed by positron emission tomographyâ€"computed tomography as a biomarker of inflammatory myopathies disease activity. Rheumatology, 2019, 58, 1459-1464.	0.9	20
76	Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective. Annals of the Rheumatic Diseases, 2019, 78, 879-889.	0.5	217
77	Acute Coronary Syndrome in Idiopathic Inflammatory Myopathies: A Population-based Study. Journal of Rheumatology, 2019, 46, 1509-1514.	1.0	13

#	Article	IF	Citations
78	MRI of skeletal muscles in patients with idiopathic inflammatory myopathies: characteristic findings and diagnostic performance in dermatomyositis. RMD Open, 2019, 5, e000850.	1.8	37
79	Idiopathic inflammatory myopathies: state of the art on clinical practice guidelines. RMD Open, 2019, 4, e000784.	1.8	19
80	Autoantibodies at the Center of (sub)Classificationâ€"Issues of Detection. JAMA Neurology, 2019, 76, 867.	4.5	6
81	Novel susceptibility alleles in HLA region for myositis and myositis specific autoantibodies in Korean patients. Seminars in Arthritis and Rheumatism, 2019, 49, 283-287.	1.6	28
82	Autoantibodies to Mi-2 alpha and Mi-2 beta in patients with idiopathic inflammatory myopathy. Rheumatology, 2019, 58, 1655-1661.	0.9	20
83	Intravenous human immunoglobulin and/or methylprednisolone pulse therapies as a possible treat-to-target strategy in immune-mediated necrotizing myopathies. Rheumatology International, 2019, 39, 1201-1212.	1.5	17
84	FRI0308â€...HIGH LEVEL OF SERUM NEOPTERIN IS ASSOCIATED WITH RAPIDLY PROGRESSIVE INTERSTITIAL LUNG DISEASE AND REDUCED SURVIVAL IN DERMATOMYOSITIS. , 2019, , .		0
85	FRI0307â€...LENABASUM, A CANNABINOID TYPE 2 RECEPTOR AGONIST, REDUCES CD4 CELL POPULATIONS AND DOWNREGULATES TYPE 1 AND 2 INTERFERON ACTIVITIES IN LESIONAL DERMATOMYOSITIS SKIN. , 2019, , .		5
86	FRI0327â€...EVALUATION OF AMERICAN COLLEGE OF RHEUMATOLOGY PROVISIONAL COMPOSITE RESPONSE INDEX IN SYSTEMIC SCLEROSIS IN A PHASE II TRIAL OF ABATACEPT VS. PLACEBO. , 2019, , .		0
87	AB0697Bâ€...VALIDATION OF 2017 CLASSIFICATION CRITERIA FOR ADULT AND JUVENILE IDIOPATHIC INFLAMMATORY MYOPATHIES PROPOSED BY EULAR/ACR IN CHINESE PATIENTS. , 2019, , .		0
88	FRI0329â€...ANALYSIS OF 11 CASES OF ANTI-PL-7 ANTIBODY POSITIVE PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES. MALIGNANCY MAY NOT BE UNCOMMON COMPLICATION IN ANTI-PL-7 ANTIBODY POSITIVE MYOSITIS PATIENTS. , 2019, , .		0
89	AB0696â€...DETECTION OF COEXISTING MYOSITIS-SPECIFIC AUTOANTIBODIES WITH LINE AND DOT IMMUNOASSAYS IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES. , 2019, , .		0
90	FRI0328â€...BRANCHED CHAIN AMINO ACIDSIN THE TREATMENT OF POLYMYOSITIS AND DERMATOMYOSITIS: RESULTS FROM THE BTOUGH STUDY. , 2019, , .		0
91	FRI0306â€...IDIOPATHIC INFLAMMATORY MYOPATHIESAND ANTISYNTHETASE SYNDROME: CONTRIBUTION OF ANTISYNTHETASE ANTIBODIES TO IMPROVE CURRENT CLASSIFICATION CRITERIA. , 2019, , .		0
92	AB0697Câ€...THE ASSOCIATION OF ANTI-MELANOMA DIFFERENTIATION-ASSOCIATED PROTEIN 5 AND SEASONAL PATTERNS IN ONSET OF IDIOPATHIC INFLAMMATORY MYOPATHIES IN KOREA. , 2019, , .		0
93	Correlation of PMN elastase and PMN elastase-to-neutrophil ratio with disease activity in patients with myositis. Journal of Translational Medicine, 2019, 17, 420.	1.8	8
94	Advances Toward Precision Medicine in Juvenile Dermatomyositis. Current Rheumatology Reports, 2019, 21, 73.	2.1	1
95	Classification of idiopathic inflammatory myopathies: pathology perspectives. Current Opinion in Neurology, 2019, 32, 704-714.	1.8	61

#	Article	IF	Citations
96	Pulmonary involvement in antisynthetase syndrome. Current Opinion in Rheumatology, 2019, 31, 603-610.	2.0	29
97	Juvenile Dermatomyositisâ€"Clinical Phenotypes. Current Rheumatology Reports, 2019, 21, 74.	2.1	38
98	Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists. Modern Rheumatology, 2019, 29, 1-19.	0.9	28
99	Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists. Journal of Dermatology, 2019, 46, e1-e18.	0.6	13
100	Significance of nailfold videocapillaroscopy in patients with idiopathic inflammatory myopathies. Rheumatology, 2019, 58, 120-130.	0.9	19
101	Is it time to depart from dichotomization in ALS diagnosis?. Clinical Neurophysiology, 2019, 130, 303-304.	0.7	0
102	Raynaudâ€™s phenomenon and antiâ€nuclear antibody are associated with pulmonary function decline in patients with dermatomyositis and polymyositis. International Journal of Rheumatic Diseases, 2019, 22, 507-515.	0.9	3
103	A pattern-based approach to the interpretation of skeletal muscle biopsies. Modern Pathology, 2019, 32, 462-483.	2.9	14
104	Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists. Neurology and Clinical Neuroscience, 2019, 7, 3-21.	0.2	6
105	Myositis-specific autoantibodies in dermatomyositis/polymyositis with interstitial lung disease. Journal of the Neurological Sciences, 2019, 397, 123-128.	0.3	28
106	Mechanic hands: clinical and capillaroscopy manifestations of patients with connective tissue diseases presented with and without mechanic hands. Clinical Rheumatology, 2019, 38, 2309-2318.	1.0	9
107	Autoantibodies in idiopathic inflammatory myopathies: Clinical associations and laboratory evaluation by mono- and multispecific immunoassays. Autoimmunity Reviews, 2019, 18, 293-305.	2.5	100
108	Safety of statin drugs in patients with dyslipidemia and stable systemic autoimmune myopathies. Rheumatology International, 2019, 39, 311-316.	1.5	9
109	Cardiorespiratory fitness in long-term juvenile dermatomyositis: a controlled, cross-sectional study of active/inactive disease. Rheumatology, 2019, 58, 492-501.	0.9	14
110	The performance of the European League Against Rheumatism/American College of Rheumatology idiopathic inflammatory myopathies classification criteria in an expert-defined 10 year incident cohort. Rheumatology, 2019, 58, 468-475.	0.9	22
111	In vivopathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy. Annals of the Rheumatic Diseases, 2019, 78, 131-139.	0.5	97
112	Diagnostic potential of sarcoplasmic myxovirus resistance protein A expression in subsets of dermatomyositis. Neuropathology and Applied Neurobiology, 2019, 45, 513-522.	1.8	56
113	Detection of myositis-specific antibodies: additional notes. Annals of the Rheumatic Diseases, 2019, 78, e29-e29.	0.5	4

#	Article	IF	Citations
114	Detection of myositis-specific antibodies. Annals of the Rheumatic Diseases, 2019, 78, e7-e7.	0.5	48
115	Detection of myositis-specific antibodies: additional notes. Annals of the Rheumatic Diseases, 2019, 78, e45-e45.	0.5	24
116	Response to: â€˜Detection of myositis-specific antibodiesâ€™ by Vulsteke et al. Annals of the Rheumatic Diseases, 2019, 78, e8-e8.	0.5	3
117	Time to personalize the treatment of anti-MDA-5 associated lung disease. Annals of the Rheumatic Diseases, 2019, 78, e52-e52.	0.5	5
118	Response to: â€˜Detection of myositis-specific antibodies: additional notesâ€™ by Infantino et al. Annals of the Rheumatic Diseases, 2019, 78, e30-e30.	0.5	3
119	Corneal Involvement of Patients with Polymyositis and Dermatomyositis. Ocular Immunology and Inflammation, 2020, 28, 58-66.	1.0	5
120	EBV-Associated Non-keratinizing Nasopharyngeal Carcinoma with Prominent Spindled Cell and Whorling Patterns: A Previously Unreported Histological Variant in a Patient Presenting with Dermatomyositis. Head and Neck Pathology, 2020, 14, 203-207.	1.3	2
121	Response to: â€˜Comment on: â€˜Idiopathic inflammatory myopathies and antisynthetase syndrome: contribution of antisynthetase antibodies to improve current classification criteriaâ€™ by Greco et alâ€™ by Knitza et al. Annals of the Rheumatic Diseases, 2020, 79, e86-e86.	0.5	4
122	Comment on: â€˜Idiopathic inflammatory myopathies and antisynthetase syndrome: contribution of antisynthetase antibodies to improve current classification criteriaâ€™ by Greco et al. Annals of the Rheumatic Diseases, 2020, 79, e85-e85.	0.5	7
123	Risk of progression of interstitial pneumonia with autoimmune features to a systemic autoimmune rheumatic disease. Rheumatology, 2020, 59, 1233-1240.	0.9	17
124	Dermatomyositis: Diagnosis and treatment. Journal of the American Academy of Dermatology, 2020, 82, 283-296.	0.6	75
125	239th ENMC International Workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14â€“16 December 2018. Neuromuscular Disorders, 2020, 30, 70-92.	0.3	148
126	The myositis clinical phenotype associated with anti-Zo autoantibodies: a case series of nine UK patients. Rheumatology, 2020, 59, 1626-1631.	0.9	10
127	Retrospective Analysis of Cancer-Associated Myositis Patients over the Past 3 Decades in a Hungarian Myositis Cohort. Pathology and Oncology Research, 2020, 26, 1749-1755.	0.9	30
128	Anti-RNP antibodies delineate a subgroup of myositis: A systematic retrospective study on 46 patients. Autoimmunity Reviews, 2020, 19, 102465.	2.5	14
129	Performance of the new EULAR/ACR classification criteria for idiopathic inflammatory myopathies (IIM) in a large monocentric IIM cohort. Seminars in Arthritis and Rheumatism, 2020, 50, 492-497.	1.6	18
130	Anti-TIF1-Î³ autoantibodies: warning lights of a tumour autoantigen. Rheumatology, 2020, 59, 469-477.	0.9	43
131	Autoantibodies in connective tissue disease. Best Practice and Research in Clinical Rheumatology, 2020, 34, 101462.	1.4	17

#	Article	IF	Citations
132	Interstitial pneumonia with autoimmune features: A single center prospective follow-up study. Autoimmunity Reviews, 2020, 19, 102451.	2.5	34
133	Needle electromyography, muscle MRI, and muscle pathology: Correlations in idiopathic inflammatory myopathies. Neurology and Clinical Neuroscience, 2020, 8, 28-35.	0.2	1
134	Current understanding and recent advances in myositis-specific and -associated autoantibodies detected in patients with dermatomyositis. Expert Review of Clinical Immunology, 2020, 16, 79-89.	1.3	14
135	Drop Head Syndrome as a Rare Complication in Mixed Connective Tissue Disease. Internal Medicine, 2020, 59, 729-732.	0.3	0
137	Patient insights on living with idiopathic inflammatory myopathy and the limitations of disease activity measurement methods â€“ a qualitative study. BMC Rheumatology, 2020, 4, 47.	0.6	9
138	Functional Progression in Patients with Interstitial Lung Disease Resulted Positive to Antisynthetase Antibodies: A Multicenter, Retrospective Analysis. Journal of Clinical Medicine, 2020, 9, 3033.	1.0	4
139	Relationship between change in physical activity and in clinical status in patients with idiopathic inflammatory myopathy: A prospective cohort study. Seminars in Arthritis and Rheumatism, 2020, 50, 1140-1149.	1.6	14
140	Update on dermatomyositis in adults. JDDG - Journal of the German Society of Dermatology, 2020, 18, 995-1013.	0.4	8
141	A novel autoantibody targeting calreticulin is associated with cancer in patients with idiopathic inflammatory myopathies. Clinical and Translational Immunology, 2020, 9, e1195.	1.7	5
142	MiR-193b modulates osteoarthritis progression through targeting ST3GAL4 via sialylation of CD44 and NF-ÐºB pathway. Cellular Signalling, 2020, 76, 109814.	1.7	10
143	Myositis-specific antibodies identify a distinct interstitial pneumonia with autoimmune features phenotype. European Respiratory Journal, 2020, 56, 2001205.	3.1	24
144	Severe muscle damage with myofiber necrosis and macrophage infiltrates characterize anti-Mi2 positive dermatomyositis. Rheumatology, 2021, 60, 2916-2926.	0.9	13
145	Increased Levels of Soluble CD206 Associated with Rapidly Progressive Interstitial Lung Disease in Patients with Dermatomyositis. Mediators of Inflammation, 2020, 2020, 1-11.	1.4	8
146	Distinct tissue injury patterns in juvenile dermatomyositis auto-antibody subgroups. Acta Neuropathologica Communications, 2020, 8, 125.	2.4	16
147	Predictors and Mortality of Rapidly Progressive Interstitial Lung Disease in Patients With Idiopathic Inflammatory Myopathy: A Series of 474 Patients. Frontiers in Medicine, 2020, 7, 363.	1.2	47
148	LEF1 mediates osteoarthritis progression through circRNF121/miR-665/MYD88 axis via NF-ÐºB signaling pathway. Cell Death and Disease, 2020, 11, 598.	2.7	33
149	Inflammatory Myopathies. Neurologic Clinics, 2020, 38, 661-678.	0.8	0
150	Line blot immunoassays in idiopathic inflammatory myopathies: retrospective review of diagnostic accuracy and factors predicting true positive results. BMC Rheumatology, 2020, 4, 28.	0.6	16

#	Article	IF	Citations
151	Soluble IL-2 Receptor in Dermatomyositis: Its Associations with Skin Ulcers and Disease Activity. Mediators of Inflammation, 2020, 2020, 1-8.	1.4	4
152	Factors Associated With Treatment Response in Patients With Idiopathic Inflammatory Myopathies: A <scp>Registryâ€Based</scp> Study. Arthritis Care and Research, 2022, 74, 468-477.	1.5	3
153	Adalimumab and myositis: A case report and review of the French and international Pharmacovigilance Databases. Neuromuscular Disorders, 2020, 30, 915-920.	0.3	5
154	Predicting Survival Across Acute Exacerbation of Interstitial Lung Disease in Patients with Idiopathic Inflammatory Myositis: The GAP-ILD Model. Rheumatology and Therapy, 2020, 7, 967-978.	1.1	7
155	Where are we moving in the classification of idiopathic inflammatory myopathies?. Current Opinion in Neurology, 2020, 33, 590-603.	1.8	68
157	Recognising the spectrum of scleromyositis: HEp-2 ANA patterns allow identification of a novel clinical subset with anti-SMN autoantibodies. RMD Open, 2020, 6, e001357.	1.8	23
158	The use and diagnostic value of testing myositis-specific and myositis-associated autoantibodies by line immuno-assay: a retrospective study. Therapeutic Advances in Musculoskeletal Disease, 2020, 12, 1759720X2097590.	1.2	16
159	Serum metabolites as biomarkers in systemic sclerosis-associated interstitial lung disease. Scientific Reports, 2020, 10, 21912.	1.6	9
160	Understanding and interpreting antinuclear antibody tests in systemic rheumatic diseases. Nature Reviews Rheumatology, 2020, 16, 715-726.	3.5	85
161	Ultra-low dose rituximab as add-on therapy in anti-MDA5-positive patients with polymyositis /dermatomyositis associated ILD. Respiratory Medicine, 2020, 172, 105983.	1.3	21
162	Juvenile dermatomyositis presenting as complete heart block in a 10-year-old girl. Paediatrics and International Child Health, 2020, 40, 251-254.	0.3	3
163	External validation of EULAR/ACR classification criteria for idiopathic inflammatory myopathies. Annals of the Rheumatic Diseases, 2022, 81, e59-e59.	0.5	1
164	Myopathies with finger flexor weakness: Not only inclusionâ€body myositis. Muscle and Nerve, 2020, 62, 445-454.	1.0	10
165	Autoantibodies as biomarkers for interstitial lung disease in idiopathic inflammatory myositis and systemic sclerosis: The case of anti-eIF2B antibodies. Journal of Translational Autoimmunity, 2020, 3, 100049.	2.0	9
166	The Spectrum of Interstitial Lung Disease Associated with Autoimmune Diseases: Data of a 3.6-Year Prospective Study from a Referral Center of Interstitial Lung Disease and Lung Transplantation â€. Journal of Clinical Medicine, 2020, 9, 1606.	1.0	22
167	Dermatomyositis induced by the secretion of Phyllomedusa bicolor or KambÃ´ frog - A case report. Toxicon, 2020, 184, 57-61.	0.8	4
168	Anti-EJ Antibody-positive Anti-synthetase Syndrome Associated with Retroperitoneal Sarcoma. Internal Medicine, 2020, 59, 2071-2076.	0.3	4
169	Interleukin-33/suppression of tumorigenicity 2 (IL-33/ST2) axis in idiopathic inflammatory myopathies and its association with laboratory and clinical parameters: a pilot study. Rheumatology International, 2020, 40, 1133-1141.	1.5	4

#	Article	IF	Citations
170	TLR expression in peripheral monocyte subsets of patients with idiopathic inflammatory myopathies: association with clinical and immunological features. Journal of Translational Medicine, 2020, 18, 125.	1.8	11
171	Clinical trials and novel therapeutics in dermatomyositis. Expert Opinion on Emerging Drugs, 2020, 25, 213-228.	1.0	9
172	Defining appropriate utilization of AST testing. Clinical Biochemistry, 2020, 79, 75-77.	0.8	9
173	Clinical Significance of Higher Cutoffs for Myositis Autoantibody Positivity Using the Euroimmun Research Line Blot: Comment on the Article by Mecoli et al. Arthritis and Rheumatology, 2020, 72, 1042-1044.	2.9	5
174	Recognition and Management of Myositis-Associated Rapidly Progressive Interstitial Lung Disease. Chest, 2020, 158, 252-263.	0.4	40
175	Myofascia-dominant involvement on whole-body MRI as a risk factor for rapidly progressive interstitial lung disease in dermatomyositis. Rheumatology, 2020, 59, 1734-1742.	0.9	13
176	Clinical practice guidance for juvenile dermatomyositis (JDM) 2018-Update. Modern Rheumatology, 2020, 30, 411-423.	0.9	31
177	Inflammatory Myopathy-Related Interstitial Lung Disease: From Pathophysiology to Treatment. Frontiers in Medicine, 2019, 6, 326.	1.2	43
178	A 21â€Yearâ€Old Woman With Joint Pain and Skin Ulceration. Arthritis Care and Research, 2021, 73, 1553-1560.	1.5	0
179	One-Year Outcome of Critically Ill Patients With Systemic Rheumatic Disease. Chest, 2020, 158, 1017-1026.	0.4	16
180	Is transient hyperCKemia a new feature of neuromyelitis optica spectrum disorders? A retrospective study in 439 patients. Journal of Neuroimmunology, 2020, 343, 577228.	1.1	2
181	Clinical manifestations and treatment of antisynthetase syndrome. Best Practice and Research in Clinical Rheumatology, 2020, 34, 101503.	1.4	62
182	Correlation of a Modified Disease Activity Score (DAS) with the Validated Original DAS in Patients with Juvenile Dermatomyositis. Journal of Rheumatology, 2021, 48, 101-104.	1.0	3
183	ILâ€15 is a biomarker involved in the development of rapidly progressive interstitial lung disease complicated with polymyositis/dermatomyositis. Journal of Internal Medicine, 2021, 289, 206-220.	2.7	30
184	Myositisâ€specific autoantibodies and their clinical associations in idiopathic inflammatory myopathies. Acta Neurologica Scandinavica, 2021, 143, 131-139.	1.0	14
185	Serum levels of galectin-3 in idiopathic inflammatory myopathies: a potential biomarker of disease activity. Rheumatology, 2021, 60, 322-332.	0.9	7
186	Assessment of diagnostic utility, clinical phenotypic associations, and prognostic significance of anti-NXP2 autoantibody in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis. Clinical Rheumatology, 2021, 40, 819-832.	1.0	16
187	Quantitative MRI in myositis patients: comparison with healthy volunteers and radiological visual assessment. Clinical Radiology, 2021, 76, 81.e1-81.e10.	0.5	9

#	Article	IF	Citations
188	Painful erythematoviolaceous nodules in dermatomyositis. Rheumatology, 2021, 60, 1573-1574.	0.9	2
190	Diagnosis and management of connective tissue diseaseâ€associated interstitial lung disease in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand*. Respirology, 2021, 26, 23-51.	1.3	45
191	The long-term prognosis of pneumomediastinum associated with dermatomyositis: a two-centre retrospective cohort study. Rheumatology, 2021, 60, 2288-2295.	0.9	7
193	From Diagnosis to Prognosis: Revisiting the Meaning of Muscle ISG15 Overexpression in Juvenile Inflammatory Myopathies. Arthritis and Rheumatology, 2021, 73, 1044-1052.	2.9	13
194	Refining myositis associated with primary SjÃ¶grenâ€™s syndrome: data from the prospective cohort ASSESS. Rheumatology, 2021, 60, 675-681.	0.9	21
195	External validation of the EULAR/ACR idiopathic inflammatory myopathies classification criteria withÂa Japanese paediatric cohort. Rheumatology, 2021, 60, 802-808.	0.9	0
196	A case with overlapping features of IgG4-related autoimmune pancreatitis, SjÃ¶grenâ€™s syndrome and anti-aminoacyl-tRNA synthetase syndrome. Modern Rheumatology Case Reports, 2021, 5, 82-86.	0.3	1
197	Long-term efficacy of adding intravenous immunoglobulins as treatment of refractory dysphagia related to myositis: a retrospective analysis. Rheumatology, 2021, 60, 1234-1242.	0.9	10
198	Cardiovascular complications in patients with idiopathic inflammatory myopathies: does heart matter in idiopathic inflammatory myopathies?. Heart Failure Reviews, 2021, 26, 111-125.	1.7	22
200	Mycophenolate in idiopathic inflammatory myositis: outcome data of a large South Asian cohort. Clinical Rheumatology, 2021, 40, 2805-2819.	1.0	3
201	Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis. Clinical Reviews in Allergy and Immunology, 2021, 60, 293-304.	2.9	81
202	Response to: â€˜Correspondence on â€˜EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroupsâ€™â€™ by Irfanet al. Annals of the Rheumatic Diseases, 2023, 82, e41-e41.	0.5	1
203	Comparison of the 2017 EULAR/ACR Criteria with Clinicoserologic Criteria for the Classification of Idiopathic Inflammatory Myopathies in Korean Patients. Yonsei Medical Journal, 2021, 62, 424.	0.9	4
204	Correspondence on â€˜EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroupsâ€™. Annals of the Rheumatic Diseases, 2023, 82, e40-e40.	0.5	1
205	Myositis Antibodies and Interstitial Lung Disease. journal of applied laboratory medicine, The, 2022, 7, 240-258.	0.6	11
206	The prevalence, clinical features, predictive factors and investigations to screen for cancer in patients with inflammatory myositis. Journal of King Abdulaziz University, Islamic Economics, 2021, 42, 100-104.	0.5	1
207	Successful Treatment of Anti-MDA5 Antibody-Positive Dermatomyositis-Associated Rapidly Progressive-Interstitial Lung Disease by Plasma Exchange: Two Case Reports. Clinical Medicine Insights: Case Reports, 2021, 14, 117954762110363.	0.3	7
208	Dermatomyositis bei Kindern und Jugendlichen. Springer Reference Medizin, 2021, , 1-37.	0.0	0

#	Article	IF	Citations
209	Expansion of circulating peripheral TIGIT+CD226+ CD4 T cells with enhanced effector functions in dermatomyositis. Arthritis Research and Therapy, 2021, 23, 15.	1.6	14
210	Clinical characteristics and management of clinically amyopathic juvenile dermatomyositis across four academic centers. Pediatric Dermatology, 2021, 38, 413-419.	0.5	2
211	Efficacy and Tolerability of Nintedanib in Idiopathic-Inflammatory-Myopathy-Related Interstitial Lung Disease: A Pilot Study. Frontiers in Medicine, 2021, 8, 626953.	1.2	17
212	Myositis-associated Interstitial Lung Disease: Clinical Characteristics and Factors Related to Pulmonary Function Improvement: A Latin-American Multicenter Cohort Study. ReumatologÃa ClÃnica, 2022, 18, 293-298.	0.2	3
213	Myostatin and markers of bone metabolism in dermatomyositis. BMC Musculoskeletal Disorders, 2021, 22, 150.	0.8	5
214	Exercise Training Attenuates Ubiquitin-Proteasome Pathway and Increases the Genes Related to Autophagy on the Skeletal Muscle of Patients With Inflammatory Myopathies. Journal of Clinical Rheumatology, 2021, 27, S224-S231.	0.5	8
215	Clinical features, muscle biopsy scores, myositis specific antibody profiles and outcome in juvenile dermatomyositis. Seminars in Arthritis and Rheumatism, 2021, 51, 95-100.	1.6	11
216	Functioning in adult patients with idiopathic inflammatory myopathy: Exploring the role of environmental factors using focus groups. PLoS ONE, 2021, 16, e0244959.	1.1	2
217	Role of MRI in idiopathic inflammatory myopathies: a review article. Acta Radiologica, 2022, 63, 200-213.	0.5	7
218	Tibia stress injury and the imaging appearance of stress fracture in juvenile dermatomyositis: six patientsâ€™ experiences. Pediatric Rheumatology, 2021, 19, 17.	0.9	1
219	Serum progranulin level is a novel tool for monitoring disease activity of dermatomyositis with antimelanoma differentiationâ€associated protein 5 antibodies. Journal of Cutaneous Immunology and Allergy, 2021, 4, 50-56.	0.2	0
220	Real world utilization of the myositis autoantibody panel. Clinical Rheumatology, 2021, 40, 3195-3205.	1.0	7
222	Anti-SAE autoantibody-positive Japanese patient with juvenile dermatomyositis complicated with interstitial lung disease - a case report. Pediatric Rheumatology, 2021, 19, 34.	0.9	9
223	Aberrantly Expressed Galectin-9 Is Involved in the Immunopathogenesis of Anti-MDA5-Positive Dermatomyositis-Associated Interstitial Lung Disease. Frontiers in Cell and Developmental Biology, 2021, 9, 628128.	1.8	10
224	Increased Levels of VCAM-1 in Sera and VLA-4 Expression on Neutrophils in Dermatomyositis with Interstitial Lung Disease. Immunological Investigations, 2022, 51, 980-992.	1.0	3
225	Multiple neurological manifestations in a patient with systemic lupus erythematosus and anti-NXP2-positive myositis. Medicine (United States), 2021, 100, e25063.	0.4	2
226	Dermatomyositis autoantibodies: how can we maximize utility?. Annals of Translational Medicine, 2021, 9, 433-433.	0.7	20
227	The balance between clinical convenience and the new concepts of the 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies. Korean Journal of Internal Medicine, 2021, 36, 288-291.	0.7	0

#	Article	IF	Citations
228	Reclassification of Korean patients with polymyositis and dermatomyositis based on the Bohan and Peter criteria by the 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies. Korean Journal of Internal Medicine, 2021, 36, 441-446.	0.7	3
230	CaracterizaciÃ³n clÃ¡nica de pacientes con miopatÃa inflamatoria en 2 instituciones de alta complejidad en Colombia: estudio descriptivo. Revista Colombiana De ReumatologÃa, 2021, 29, 9-9.	0.0	2
232	Management of Myositis-Associated Interstitial Lung Disease. Medicina (Lithuania), 2021, 57, 347.	0.8	38
233	Clinical Characteristics of Myositis Associated with Graft-Versus-Host Disease. Current Rheumatology Reports, 2021, 23, 30.	2.1	9
234	Anti-MDA5 Antibody-Positive Interstitial Pneumonia with Autoimmune Features Presenting as Amyopathic Hypodermatitic Dermatomyositis: A Case Report. Case Reports in Dermatology, 2021, 13, 222-229.	0.3	1
235	UNC13D mutation in a patient with juvenile polymyositis with recurrent macrophage activation syndrome. Rheumatology, 2021, 60, e404-e406.	0.9	2
236	Clinical features of acute fibrinous and organizing pneumonia: An early histologic pattern of various acute inflammatory lung diseases. PLoS ONE, 2021, 16, e0249300.	1.1	15
237	Juvenile Dermatomyositis: Advances in Pathogenesis, Assessment, and Management. Current Pediatric Reviews, 2021, 17, 273-287.	0.4	6
238	Detection of multiple myositis-specific autoantibodies in unique patients with idiopathic inflammatory myopathy: A single centre-experience and literature review. Seminars in Arthritis and Rheumatism, 2021, 51, 486-494.	1.6	8
239	Geographical Latitude Remains as an Important Factor for the Prevalence of Some Myositis Autoantibodies: A Systematic Review. Frontiers in Immunology, 2021, 12, 672008.	2.2	8
240	Nailfold capillaroscopy findings in cutaneous lupus erythematosus patients with or without digital lesions and comparison with dermatomyositis patients: A prospective study. Lupus, 2021, 30, 1207-1213.	0.8	7
241	Risk of primary graft dysfunction following lung transplantation in selected adults with connective tissue disease-associated interstitial lung disease. Journal of Heart and Lung Transplantation, 2021, 40, 351-358.	0.3	7
242	Disease characteristics and clinical outcomes of adults and children with anti-MDA-5 antibody-associated myositis: a prospective observational bicentric study. Rheumatology International, 2022, 42, 1155-1165.	1.5	10
243	Juvenile Dermatomyositis Presenting with Erythematous Swelling of the Upper Eyelid. Journal of Korean Ophthalmological Society, 2021, 62, 719-723.	0.0	0
244	Texture analysis of muscle MRI: machine learning-based classifications in idiopathic inflammatory myopathies. Scientific Reports, 2021, 11, 9821.	1.6	28
245	Concurrent Myotonic Dystrophy and Inflammatory Myopathy in a Patient with HIV/AIDS. Case Reports in Infectious Diseases, 2021, 2021, 1-3.	0.2	0
246	Anti-HMGCR myopathy overlaps with dermatomyositis-like rash: a distinct subtype of idiopathic inflammatory myopathy. Journal of Neurology, 2022, 269, 280-293.	1.8	9
247	Anti-tRNA synthetase syndrome interstitial lung disease: A single center experience. Respiratory Medicine, 2022, 191, 106432.	1.3	2

#	Article	IF	Citations
248	The Autoantigen Repertoire and the Microbial RNP World. Trends in Molecular Medicine, 2021, 27, 422-435.	3.5	4
249	MiopatÃas inflamatorias idiopÃ¡ticas. Medicine, 2021, 13, 1799-1808.	0.0	0
250	Juvenile idiopathic inflammatory myopathies with antiâ€3â€hydroxyâ€3â€methylglutarylâ€coenzyme A reductase antibodies in a Chinese cohort. CNS Neuroscience and Therapeutics, 2021, 27, 1041-1047.	1.9	4
251	Antiphospholipid antibodies and anticoagulant therapy: capillaroscopic findings. Arthritis Research and Therapy, 2021, 23, 175.	1.6	11
252	Anti-nuclear matrix protein 2 antibody-positive inflammatory myopathies represent extensive myositis without dermatomyositis-specific rash. Rheumatology, 2022, 61, 1222-1227.	0.9	32
253	Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. Annals of the Rheumatic Diseases, 2021, 80, 1330-1338.	0.5	503
254	Long-term clinical course and outcome in patients with primary SjÃ¶gren syndrome-associated interstitial lung disease. Scientific Reports, 2021, 11, 12827.	1.6	11
255	Interstitial pneumonia with autoimmune features: from research classification to diagnosis. Current Opinion in Pulmonary Medicine, 2021, 27, 374-387.	1.2	1
256	Incidence, severity and clinical manifestations of juvenile dermatomyositis among Maori and Pacific Island compared to European children. Journal of Paediatrics and Child Health, 2021, 57, 1881-1885.	0.4	3
257	Polymyositis Presenting with Isolated Periorbital Edema: a Case-Based Review. SN Comprehensive Clinical Medicine, 2021, 3, 2033-2037.	0.3	0
258	A Case Report of Anorectal Squamous Cell Carcinoma Associated with Overlap Myositis Syndromeâ€"a Possible Paraneoplastic Myositis Syndrome. Clinical Colorectal Cancer, 2021, 20, 148-152.	1.0	1
259	Autoantibody profiles delineate distinct subsets of scleromyositis. Rheumatology, 2022, 61, 1148-1157.	0.9	16
260	Characterization of Patients With Dermatomyositis According to Antiâ€"Melanoma Differentiation-Associated Gene-5 Autoantibodies in Centers from 3 Latin American Countries. Journal of Clinical Rheumatology, 2022, 28, e444-e448.	0.5	5
261	Assessment of antinuclear antibodies (ANA): National recommendations on behalf of the Croatian society of medical biochemistry and laboratory medicine. Biochemia Medica, 2021, 31, 210-229.	1.2	9
262	Clinical Characteristics of Lipid Metabolism in Untreated Patients with Anti-MDA5 Antibody-Positive. International Journal of General Medicine, 2021, Volume 14, 2507-2512.	0.8	1
263	Severe polymyositis occurring in a cancer patient directly after chemotherapy: etiology and management. Future Science OA, 2021, 7, FSO706.	0.9	1
264	Adolescent-onset anti-MDA5 antibody-positive juvenile dermatomyositis with rapidly progressive interstitial lung disease and spontaneous pneumomediastinum: a case report and literature review. Pediatric Rheumatology, 2021, 19, 103.	0.9	11
265	The lungs were on fire: a pilot study of 18F-FDG PET/CT in idiopathic-inflammatory-myopathy-related interstitial lung disease. Arthritis Research and Therapy, 2021, 23, 198.	1.6	13

#	Article	IF	Citations
266	Veno-Venous Extracorporeal Membrane Oxygenation for Myositis-Associated Rapidly Progressive Interstitial Lung Disease. Chest, 2021, 160, 2163-2167.	0.4	5
267	ISHLT consensus document on lung transplantation in patients with connective tissue disease: Part I: Epidemiology, assessment of extrapulmonary conditions, candidate evaluation, selection criteria, and pathology statements. Journal of Heart and Lung Transplantation, 2021, 40, 1251-1266.	0.3	11
268	Clinical role of bronchoalveolar lavage in dermatomyositis-associated interstitial lung disease. Rheumatology, 2021, 61, 345-354.	0.9	10
269	Limb girdle muscular dystrophy R12 (LGMD 2L, anoctaminopathy) mimicking idiopathic inflammatory myopathy: key points to prevent misdiagnosis. Rheumatology, 2022, 61, 1645-1650.	0.9	10
271	Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial. Nature Medicine, 2021, 27, 1744-1751.	15.2	148
272	Performance of myositisâ€specific antibodies detected on myositis line immunoassay to diagnose and subâ€classify patients with suspected idiopathic inflammatory myopathy, a retrospective recordsâ€based review. International Journal of Rheumatic Diseases, 2021, 24, 1167-1175.	0.9	4
273	Juvenile dermatomyositis in Thai children: Retrospective review of 30 cases from a tertiary care center. Indian Journal of Dermatology, Venereology and Leprology, 2021, 88, 162-170.	0.2	4
274	Evaluation of Prognostic Factors in Anti-MDA5 Antibody-Positive Patients in Chongqing, China: A Retrospective Study. International Journal of General Medicine, 2021, Volume 14, 4775-4781.	0.8	6
275	Anasarca as the presenting symptom of juvenile dermatomyositis: a case series. Pediatric Rheumatology, 2021, 19, 120.	0.9	7
276	Siglec-1 expression on monocytes is associated with the interferon signature in juvenile dermatomyositis and can predict treatment response. Rheumatology, 2022, 61, 2144-2155.	0.9	20
277	Serum Amphiregulin and Heparin-Binding Epidermal Growth Factor as Biomarkers in Patients with Idiopathic Inflammatory Myopathy. Journal of Clinical Medicine, 2021, 10, 3730.	1.0	5
278	An itchy rash and muscle weakness. Clinical Case Reports (discontinued), 2021, 9, e04750.	0.2	0
279	InÂvitro diagnostics for the medical dermatologist. Part I: Autoimmune tests. Journal of the American Academy of Dermatology, 2021, 85, 287-298.	0.6	2
280	The phenotype of myositis patients with anti-Ku autoantibodies. Seminars in Arthritis and Rheumatism, 2021, 51, 728-734.	1.6	13
282	Re-evaluation of the prognostic significance of oropharyngeal dysphagia in idiopathic inflammatory myopathies. Scandinavian Journal of Rheumatology, 2022, 51, 402-410.	0.6	1
283	A Japanese Patient with Anti-PM/Scl and Centromere Antibody-Positive Scleroderma-Amyopathic Dermatomyositis Overlap Syndrome Who Developed Renal Crisis. Modern Rheumatology Case Reports, 2021, , .	0.3	1
284	Polymyositis: does it really exist as a distinct clinical subset?. Current Opinion in Rheumatology, 2021, 33, 537-543.	2.0	13
285	Updates on Juvenile Dermatomyositis from the Last Decade: Classification to Outcomes. Rheumatic Disease Clinics of North America, 2021, 47, 669-690.	0.8	8

#	Article	IF	Citations
286	Incidence, Prevalence, and Mortality of Dermatomyositis: A <scp>Populationâ€Based</scp> Cohort Study. Arthritis Care and Research, 2023, 75, 348-355.	1.5	16
287	NK Cell Patterns in Idiopathic Inflammatory Myopathies with Pulmonary Affection. Cells, 2021, 10, 2551.	1.8	8
288	A Clinical Risk Model to Predict Rapidly Progressive Interstitial Lung Disease Incidence in Dermatomyositis. Frontiers in Medicine, 2021, 8, 733599.	1.2	6
289	Performance of the 2017 European Alliance of Associations for Rheumatology/American College of Rheumatology Classification Criteria for Idiopathic Inflammatory Myopathies in Patients With <scp>Myositisâ€Specific</scp> Autoantibodies. Arthritis and Rheumatology, 2022, 74, 508-517.	2.9	24
290	Distribution and trajectory of direct and indirect costs of idiopathic inflammatory myopathies. Seminars in Arthritis and Rheumatism, 2021, 51, 983-988.	1.6	6
291	Diagnosis of myositis-associated interstitial lung disease: Utility of the myositis autoantibody line immunoassay. Respiratory Medicine, 2021, 187, 106581.	1.3	4
292	Predictors for progressive fibrosis in patients with connective tissue disease associated interstitial lung diseases. Respiratory Medicine, 2021, 187, 106579.	1.3	21
293	Development and Preliminary Validation of an Electromyography-Scoring Protocol for the Assessment and Grading of Muscle Involvement in Patients With Juvenile Idiopathic Inflammatory Myopathies. Pediatric Neurology, 2021, 124, 6-10.	1.0	2
294	Anti-PL-7 antibody-positive dermatomyositis with progressive interstitial pneumonia complicated with tracheal ulcer. Respiratory Medicine Case Reports, 2021, 33, 101449.	0.2	0
295	Characteristics and outcomes of overlap myositis: a comparative multigroup cohort study in adults from the MyoCite cohort. Rheumatology International, 2021, 41, 551-563.	1.5	12
296	Idiopathic inflammatory myopathies - new advances. Neurologie Pro Praxi, 2021, 21, 477-484.	0.0	0
297	Assessment of a Line Immunoassay for the Detection of Mi-2 Antibodies: Results From a Single Academic Center Investigation. American Journal of Clinical Pathology, 2022, 157, 506-509.	0.4	1
298	Community-Acquired Pneumonia and Hospital-Acquired Pneumonia in Adult Patients with Idiopathic Inflammatory Myopathy: Outcome and Antibiotic Therapy. Rheumatology and Therapy, 2021, 8, 255-272.	1.1	4
299	Polymyositis: is there anything left? A retrospective diagnostic review from a tertiary myositis centre. Rheumatology, 2021, 60, 3398-3403.	0.9	27
300	Identification of a novel autoantigen eukaryotic initiation factor 3 associated with polymyositis. Rheumatology, 2020, 59, 1026-1030.	0.9	16
301	The Patients' Perspective of Important Glucocorticoid Effects. Journal of Clinical Rheumatology, 2021, 27, 232-238.	0.5	5
302	Correspondence on â€˜Machine learning algorithms reveal unique gene expression profiles in muscle biopsies from patients with different types of myositisâ€™. Annals of the Rheumatic Diseases, 2023, 82, e61-e61.	0.5	2
303	High pre-treatment neutrophil-to-lymphocyte ratio in patients with dermatomyositis/polymyositis predicts an increased risk of cancer. European Journal of Dermatology, 2020, 30, 133-139.	0.3	2

#	Article	IF	Citations
304	Toward Earlier Diagnosis Using Combined eHealth Tools in Rheumatology: The Joint Pain Assessment Scoring Tool (JPAST) Project. JMIR MHealth and UHealth, 2020, 8, e17507.	1.8	26
305	Muscle Ultrasound in Inflammatory Myopathies: A Critical Review. Journal of Rheumatic Diseases and Treatment, 2019, 5, .	0.1	4
306	Tofacitinib as a Treatment for Refractory Dermatomyositis: A Case Report. Open Journal of Rheumatology and Autoimmune Diseases, 2020, 10, 39-43.	0.1	1
307	Hemophagocytic Lymphohistiocytosis in Dermatomyositis. Balkan Medical Journal, 2019, 36, 62-63.	0.3	1
309	OUP accepted manuscript. journal of applied laboratory medicine, The, 2022, 7, 387-390.	0.6	2
310	OUP accepted manuscript. journal of applied laboratory medicine, The, 2022, 7, 114-136.	0.6	0
311	Left ventricle diastolic dysfunction in idiopathic inflammatory myopathies: A meta-analysis and systematic review. Modern Rheumatology, 2021, , .	0.9	1
312	Decrease of infectious complications in outpatients with autoimmune diseases from 2019 to 2020 under the COVID-19 pandemic: A single-centre, retrospective cohort study in Japan. Modern Rheumatology, 0, , .	0.9	0
313	Comparisons of Anti-dsDNA Antibody Detection Methods by Chemiluminescent Immunoassay and Enzyme-Linked Immunosorbent Assay in Systemic Lupus Erythematosus. Diagnostics, 2021, 11, 1940.	1.3	1
314	Vacuolar Myopathy Associated to CACNA1S Mutation as a Rare Cause of Late-Onset Limb-Girdle Myopathy: A Case Report. Cureus, 2021, 13, e18873.	0.2	4
315	Association of extended myositis panel results, clinical features, and diagnoses: a single-center retrospective observational study. Rheumatology International, 2021, 41, 2133-2146.	1.5	3
317	Polymyositis and dermatomyositis: ocular manifestations and potential sight-threatening complications. Rheumatology International, 2022, 42, 1119-1131.	1.5	5
318	Plasma exosomal RNAs have potential as both clinical biomarkers and therapeutic targets of dermatomyositis. Rheumatology, 2022, 61, 2672-2681.	0.9	12
320	Idiopathic inflammatory myopathies. Vnitrni Lekarstvi, 2018, 64, 155-163.	0.1	1
321	Myositis. Contemporary Clinical Neuroscience, 2019, , 787-808.	0.3	0
322	Idiopathische entzÃ¼ndliche Myopathien bei Kindern und Jugendlichen. Springer Reference Medizin, 2019, , 1-4.	0.0	0
323	A Case of Small Cell Lung Cancer with Anti-Transcription Intermediary Factor 1 (TIF1)-Î³ Antibody-positive Dermatomyositis as Paraneoplastic Syndrome. Japanese Journal of Lung Cancer, 2019, 59, 158-162.	0.0	2
324	Idiopathic inflammatory myopathies: difficulties of diagnosis. Ukrainian Therapeutical Journal, 2019, .	0.0	0

#	Article	IF	Citations
325	Pulmonary involvement in inflammatory myopathies. , 2019, , 68-89.		1
326	Making the Diagnosis of Myositis: Definition and Classification of Myositis. , 2020, , 91-98.		0
327	Cyclophosphamide Versus Obinutuzumab for the Treatment of Anti-MDA5 Positive Inflammatory Myopathy with Interstitial Lung Disease: A Study Protocol and LiteratureÂReview. Journal of Clinical Rheumatology and Immunology, 2019, 19, 53-58.	0.4	0
328	Polymyositis Presenting as Rhabdomyolysis After the Initiation of Omeprazole. Cureus, 2020, 12, e8125.	0.2	2
329	Cancer alertness in patients with rheumatic diseases. Sovremennaya Revmatologiya, 2020, 14, 117-122.	0.1	0
330	A prospective multicenter study assessing humoral immunogenicity and safety of the mRNA SARS-CoV-2 vaccines in Greek patients with systemic autoimmune and autoinflammatory rheumatic diseases. Journal of Autoimmunity, 2021, 125, 102743.	3.0	45
331	Pediatric autoimmune connective tissue diseases â€“ epidemiology, clinical manifestations, diagnosis and treatment. Pediatru Ro, 2020, 1, 18.	0.0	0
332	Digestive vasculitis: a rare but severe complication of NXP2 dermatomyositis. Rheumatology, 2021, 60, e165-e166.	0.9	2
333	Inflammatory Muscle Disease. , 2021, , 95-105.		0
335	Ä°nflamatuar miyozitler: Ä°diyopatik mi? Ã‡akÄ±ÅŸma mÄ±? Paraneoplastik mi?. Ege TÄ±p Dergisi, 0, , 51-57.	0.1	0
336	Myositis-specific Autoantibodies Reacting to Both Tif1gamma and Mi-2 in a Patient with Juvenile Dermatomyositis. Acta Dermato-Venereologica, 2020, 100, adv00238.	0.6	2
337	Inflammatory Myopathies. , 2020, , 1377-1392.		0
338	Idiopathische entzÃ¼ndliche Myopathien. Springer Reference Medizin, 2020, , 2693-2696.	0.0	0
339	Epidemiology and clinical characteristics of systemic sclerosis overlap syndrome (SSc-OS), and the factors significantly associated with SSc-OS in Thai patients with systemic sclerosis. Modern Rheumatology, 2021, , .	0.9	3
340	Rituximab for interstitial pneumonia with autoimmune features at two medical centres. Rheumatology Advances in Practice, 2021, 5, ii1-ii9.	0.3	7
341	Characteristics of dermatomyositis patients with and without associated malignancy. JDDG - Journal of the German Society of Dermatology, 2021, 19, 1601-1611.	0.4	9
342	An unusual case of enterovirus infection with polymyositis and severe necrotizing retinovasculitis in a 10-year-old boy. Rheumatology, 2021, , .	0.9	0
343	Paraneoplastic Necrotizing Myopathy Post Lumpectomy and Chemotherapy for Early Breast Cancer. Cureus, 2020, 12, e10916.	0.2	0

#	Article	IF	Citations
344	Exploring Road of Classification Criteria for Idiopathic Inflammatory Myopathy. Chinese Medical Journal, 2018, 131, 2773-2775.	0.9	0
345	Dysregulated expression profile of myomiRs in the skeletal muscle of patients with polymyositis. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2019, 30, 237-245.	0.7	10
347	Anterior segment parameters associated with extramuscular manifestations in polymyositis and dermatomyositis. International Journal of Ophthalmology, 2020, 13, 1443-1450.	0.5	1
348	Respiratory Failure in a Rare Case of Juvenile Dermatomyositis - Systemic Scleroderma Overlap Syndrome. MÃ¦dica, 2020, 15, 394-400.	0.4	0
350	Adult idiopathic inflammatory myopathies. Medicine, 2022, 50, 70-75.	0.2	4
351	Performance of ENMC and EULAR/ACR classification systems applied to a single tertiary center cohort of dermatomyositis patients. Neurological Research and Practice, 2021, 3, 59.	1.0	2
352	GAP Score and CA-153 Associated with One-Year Mortality in Anti-MDA-5 Antibody-Positive Patients: A Real-World Experience. Journal of Clinical Medicine, 2021, 10, 5241.	1.0	8
353	Clinical features and diagnostic tools in idiopathic inflammatory myopathies. Critical Reviews in Clinical Laboratory Sciences, 2022, 59, 219-240.	2.7	6
354	Serum KL-6 as predictive and prognostic marker of interstitial lung disease in childhood connective tissue diseases: a pilot study. Reumatismo, 2021, 73, .	0.4	2
355	Profiling of Myositis Specific Antibodies and Composite Scores as an Aid in the Differential Diagnosis of Autoimmune Myopathies. Diagnostics, 2021, 11, 2246.	1.3	10
356	Radiological Characteristics of Patients With Anti-MDA5â€“Antibody-Positive Dermatomyositis in 18F-FDG PET/CT: A Pilot Study. Frontiers in Medicine, 2021, 8, 779272.	1.2	7
357	Charakteristika von Dermatomyositisâ€Patienten mit und ohne Malignomâ€Assoziation. JDDG - Journal of the German Society of Dermatology, 2021, 19, 1601-1612.	0.4	1
358	What Is in the Myopathy Literature?. Journal of Clinical Neuromuscular Disease, 2021, 23, 66-74.	0.3	0
359	Idiopathic inflammatory myopathies. Nature Reviews Disease Primers, 2021, 7, 86.	18.1	212
360	Clinical Characteristics and Management of Patients With Clinical Amyopathic Dermatomyositis: A Retrospective Study of 64 Patients at a Tertiary Dermatology Department. Frontiers in Medicine, 2021, 8, 783416.	1.2	4
361	The spectrum of hemophagocytic lymphohistiocytosis: a retrospective study comparing adult macrophage activation syndrome to malignancy-associated hemophagocytic lymphohistiocytosis. Rheumatology International, 2022, 42, 1247-1255.	1.5	1
362	Autoantibodies in the disease criteria for systemic sclerosis: The need for specification for optimal application. Journal of Translational Autoimmunity, 2022, 5, 100141.	2.0	8
363	Anterior segment parameters associated with extramuscular manifestations in polymyositis and dermatomyositis. International Journal of Ophthalmology, 2020, 13, 1443-1450.	0.5	5

#	Article	IF	Citations
364	Clinically amyopathic dermatomyositis associated with anti-nuclear matrix protein 2 antibody. Rheumatology Advances in Practice, 2021, 5, rkab104.	0.3	2
365	Coronary Heart Disease and Cardiovascular Risk Factors in Patients With Idiopathic Inflammatory Myopathies: A Systemic Review and Meta-Analysis. Frontiers in Medicine, 2021, 8, 808915.	1.2	2
366	Dermatomyositis Following BNT162b2 mRNA COVID-19 Vaccination. Journal of Korean Medical Science, 2022, 37, e32.	1.1	31
367	Systemic sclerosis complicated with renal thrombotic microangiopathy: a case report and literature review. BMC Nephrology, 2022, 23, 22.	0.8	4
368	Anti-RuvBL1/2 autoantibodies in patients with systemic sclerosis or idiopathic inflammatory myopathy and a nuclear speckled pattern. Annals of the Rheumatic Diseases, 2022, 81, 742-744.	0.5	7
369	Do histopathological features correlate with systemic manifestations in dermatomyositis? Analysis of 42 skin biopsy specimens from 22 patients. Journal of Cutaneous Pathology, 2022, , .	0.7	3
370	Growth differentiation factor-15 as an emerging biomarker for identifying myositis. Expert Review of Clinical Immunology, 2022, 18, 115-123.	1.3	3
371	Outcome predictors of immune-mediated necrotizing myopathyâ€"a retrospective, multicentre study. Rheumatology, 2022, 61, 3824-3829.	0.9	5
372	An Italian Multicenter Study on Anti-NXP2 Antibodies: Clinical and Serological Associations. Clinical Reviews in Allergy and Immunology, 2022, 63, 240-250.	2.9	6
373	Skin pigmentation in antisynthetase syndrome. Journal of Cosmetic Dermatology, 2022, 21, 4097-4098.	0.8	0
374	Replacement and Immunomodulatory Activities of 20% Subcutaneous Immunoglobulin Treatment: A Single-Center Retrospective Study in Autoimmune Myositis and CVID Patients. Frontiers in Immunology, 2021, 12, 805705.	2.2	7
375	Management of MDA-5 antibody positive clinically amyopathic dermatomyositis associated interstitial lung disease: A systematic review. Seminars in Arthritis and Rheumatism, 2022, 53, 151959.	1.6	44
376	Concordance between myositis autoantibodies and anti-nuclear antibody patterns in a real-world, Australian cohort. Rheumatology, 2022, , .	0.9	4
377	Clinical features and immune-related protein patterns of anti-MDA5 positive clinically amyopathic dermatomyositis Dutch patients. Rheumatology, 2022, 61, 4087-4096.	0.9	4
378	Antinuclear Antibody (ANA) and Anti-Mi-2-Alpha Positive Dermatomyositis Hinting a Cancer Diagnosis. Cureus, 2022, 14, e21844.	0.2	1
379	Cancer screening in idiopathic inflammatory myopathies: Ten years experience from a single center. Seminars in Arthritis and Rheumatism, 2022, 53, 151940.	1.6	5
380	Autoantibody Markers of Increased Risk of Malignancy in Patients with Dermatomyositis. Clinical Reviews in Allergy and Immunology, 2022, 63, 289-296.	2.9	19
381	Tumor markers are associated with rapidly progressive interstitial lung disease in adult-dermatomyositis. Clinical Rheumatology, 2022, 41, 1731-1739.	1.0	10

#	Article	IF	Citations
382	Positioning of myositis-specific and associated autoantibody (MSA/MAA) testing in disease criteria and routine diagnostic work-up. Journal of Translational Autoimmunity, 2022, 5, 100148.	2.0	4
383	Trichoscopic Signs in Dermatomyositis, Systemic Lupus Erythematosus, and Systemic Sclerosis: A Comparative Study of 150 Patients. Dermatology, 2022, 238, 677-687.	0.9	7
384	Myositis-associated interstitial lung disease: a comprehensive approach to diagnosis and management. Clinical and Experimental Rheumatology, 2021, , .	0.4	0
385	Polymyositis Presenting With Nontraumatic Rhabdomyolysis and Dysphagia: A Case Report. Journal of Investigative Medicine High Impact Case Reports, 2022, 10, 232470962210745.	0.3	3
386	Inflammatory myopathy, mixed connective tissue disease, and antisynthetase syndrome. Handbook of Systemic Autoimmune Diseases, 2022, , 105-151.	0.1	0
387	A rare case of suspected lupus erythematosus panniculitis as the presenting skin feature of juvenile dermatomyositis: A case report. SAGE Open Medical Case Reports, 2022, 10, 2050313X2210863.	0.2	1
388	Clinical characterization of patients with inflammatory myopathy in 2 tertiary care hospitals in Colombia: A descriptive survey. Revista Colombiana De ReumatologÃa (English Edition), 2022, 29, 9-18.	0.1	0
389	Clinical characteristics and prognostic factors of fibrotic nonspecific interstitial pneumonia. Therapeutic Advances in Respiratory Disease, 2022, 16, 175346662210894.	1.0	6
390	Progressive, refractory macrophage activation syndrome as the initial presentation of anti-MDA5 antibody positive juvenile dermatomyositis: a case report and literature review. Pediatric Rheumatology, 2022, 20, 16.	0.9	7
391	Machine Learning Algorithms Identify Clinical Subtypes and Cancer in Anti-TIF1Î³+ Myositis: A Longitudinal Study of 87 Patients. Frontiers in Immunology, 2022, 13, 802499.	2.2	4
392	Myositis-associated interstitial lung disease: a comprehensive approach to diagnosis and management. Clinical and Experimental Rheumatology, 2022, 40, 373-383.	0.4	18
393	Case Report: Simultaneously Developed Amyopathic Dermatomyositis and Autoimmune Sclerosing Cholangitis â€“ a Coincidence or a Shared Immunopathogenesis?. Frontiers in Immunology, 2022, 13, 825799.	2.2	0
394	High-Dimensional Analysis Reveals Distinct Endotypes in Patients With Idiopathic Inflammatory Myopathies. Frontiers in Immunology, 2022, 13, 756018.	2.2	4
395	SIGLEC1 enables straightforward assessment of type I interferon activity in idiopathic inflammatory myopathies. RMD Open, 2022, 8, e001934.	1.8	16
396	Inflammatory myopathies overlapping with systemic sclerosis: a systematic review. Clinical Rheumatology, 2022, 41, 1951-1963.	1.0	6
397	Safety and immunogenicity of BNT162b2 mRNA COVID-19 vaccine in adolescents with rheumatic diseases treated with immunomodulatory medications. Rheumatology, 2022, 61, 4263-4272.	0.9	29
398	Modification of Intestinal Microbiota Dysbiosis by Low-Dose Interleukin-2 in Dermatomyositis: A Post Hoc Analysis From a Clinical Trial Study. Frontiers in Cellular and Infection Microbiology, 2022, 12, 757099.	1.8	9
399	Generalised oedema as a presenting manifestation of inflammatory myopathy. BMJ Case Reports, 2022, 15, e248036.	0.2	0

#	Article	IF	Citations
400	Angioedemaâ€like presentation as the presenting finding of juvenile myositis and juvenile dermatomyositis in 2 patients. International Journal of Rheumatic Diseases, 2022, , .	0.9	0
401	Interstitial pneumonia with autoimmune features: Evaluation of connective tissue disease incidence during follow-up. European Journal of Internal Medicine, 2022, 97, 62-68.	1.0	10
402	Muscle Biopsy: A Requirement for Precision Medicine in Adult-Onset Myopathy. Journal of Clinical Medicine, 2022, 11, 1580.	1.0	4
403	Antiâ€Jo1 autoantibodies, from clinic to the bench. Rheumatology & Autoimmunity, 2022, 2, 57-68.	0.3	5
404	Identification of Similarities Between Skin Lesions in Patients With Antisynthetase Syndrome and Skin Lesions in Patients With Dermatomyositis by Highly Multiplexed Imaging Mass Cytometry. Arthritis and Rheumatology, 2022, 74, 882-891.	2.9	3
405	Concurrent myopathy and inflammatory cardiac disease in COVID-19 patients: a case series and literature review. Rheumatology International, 2022, 42, 905-912.	1.5	11
406	Humoral and Cellular Immunogenicity and Safety of Five Different SARS-CoV-2 Vaccines in Patients With Autoimmune Rheumatic and Musculoskeletal Diseases in Remission or With Low Disease Activity and in Healthy Controls: A Single Center Study. Frontiers in Immunology, 2022, 13, 846248.	2.2	19
407	Statin-associated immune-mediated necrotizing myositis in Native Americans. Rheumatology, 2022, 61, 4855-4862.	0.9	5
408	The Role of Myositis-Specific Autoantibodies in the Dermatomyositis Spectrum. Cureus, 2022, 14, e22978.	0.2	4
409	The differential diagnosis of IgG4-related disease based on machine learning. Arthritis Research and Therapy, 2022, 24, 71.	1.6	2
410	Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases. Annals of the Rheumatic Diseases, 2022, 81, 1036-1043.	0.5	30
411	Investigating characteristics of idiopathic inflammatory myopathy flares using daily symptom data collected via a smartphone app. Rheumatology, 2022, 61, 4845-4854.	0.9	4
412	Nailfold microvascular abnormalities are associated with a higher prevalence of pulmonary arterial hypertension in patients with MCTD. Rheumatology, 2022, 61, 4875-4884.	0.9	5
413	An 8-Year-Old Boy With Prolonged Fever and Subcutaneous Nodules. Pediatrics, 2022, 149, .	1.0	0
414	Development of organâ€specific autoimmunity by dysregulated Aire expression. Immunology and Cell Biology, 2022, , .	1.0	1
416	Rescue Treatment with Infliximab for a Bilateral, Severe, Sight Threatening Frosted Branch Angiitis Associated with Concomitant Acute Onset of Presumed Dermatomyositis. Ocular Immunology and Inflammation, 2022, , 1-5.	1.0	1
417	Imaging Review of Connective Tissue Diseases. Contemporary Diagnostic Radiology, 2022, 45, 1-7.	0.1	0
418	Dermatomyositis post vaccine against SARS-COV2. BMC Rheumatology, 2022, 6, 20.	0.6	19

#	Article	IF	Citations
419	Antibody Therapies in Autoimmune Inflammatory Myopathies: Promising Treatment Options. Neurotherapeutics, 2022, 19, 911-921.	2.1	7
421	Reliability of antinuclear matrix protein 2 antibody assays in idiopathic inflammatory myopathies is dependent on target protein properties. Journal of Dermatology, 2022, 49, 441-447.	0.6	3
422	Efficacy and safety of plasma exchange in interstitial lung diseases with anti-melanoma differentiation-associated 5 gene antibody positive clinically amyopathic dermatomyositis. Scandinavian Journal of Rheumatology, 2023, 52, 77-83.	0.6	3
424	Autoimmune Progressive Fibrosing Interstitial Lung Disease: Predictors of Fast Decline. Frontiers in Pharmacology, 2021, 12, 778649.	1.6	9
425	Salivary gland ultrasonography in patients with connective tissue diseases: a multi-centre observational study. Rheumatology, 2021, , .	0.9	2
426	New Onset of Autoimmune Diseases Following COVID-19 Diagnosis. Cells, 2021, 10, 3592.	1.8	135
428	Gathering patients and rheumatologists' perceptions to improve outcomes in idiopathic inflammatory myopathies. Clinics, 2022, 77, 100031.	0.6	2
429	A machine learning analysis to predict the response to intravenous and subcutaneous immunoglobulin in inflammatory myopathies. A proposal for a future multi-omics approach in autoimmune diseases. Autoimmunity Reviews, 2022, 21, 103105.	2.5	17
430	Evaluation and validation of the prognostic value of anti-MDA5 IgG subclasses in dermatomyositis-associated interstitial lung disease. Rheumatology, 2022, 62, 397-406.	0.9	8
431	Thromboembolic events in idiopathic inflammatory myopathy: a retrospective study in China. Clinical Rheumatology, 2022, , 1.	1.0	2
432	Performance of timed function tests as outcome measures in idiopathic inflammatory myopathy â€“ results from a single-centre cohort. Rheumatology, 2022, , .	0.9	2
433	The Expression of Cytokine Profiles and Related Receptors in Idiopathic Inflammatory Myopathies. Frontiers in Pharmacology, 2022, 13, 852055.	1.6	7
434	The Role of Quantitative and Semi-quantitative [18F]FDG-PET/CT Indices for Evaluating Disease Activity and Management of Patients With Dermatomyositis and Polymyositis. Frontiers in Medicine, 2022, 9, 883727.	1.2	2
438	Phenotypic clusters and survival analyses in interstitial pneumonia with myositis-specific autoantibodies.. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2022, 38, e2021047.	0.2	2
440	Recent research on myositis-specific autoantibodies in juvenile dermatomyositis. Chinese Journal of Contemporary Pediatrics, 2021, 23, 1064-1068.	0.2	2
443	Diagnostic Value of Anti-Nuclear Antibodies: Results From Korean University-Affiliated Hospitals. Journal of Korean Medical Science, 2022, 37, e159.	1.1	4
444	Clinical profile of anti-transcription intermediary factor-1 gamma-positive adults from a single tertiary care center. Current Medical Issues, 2022, 20, 99.	0.1	0
445	Clinical spectrum and outcomes of patients with anti-jo1 positive antisynthetase syndrome seen at a single tertiary care hospital in North India. Indian Journal of Rheumatology, 2023, 18, 40.	0.2	0

#	Article	IF	Citations
447	Screening for Anti-HMGCR Antibodies in a Large Single Myositis Center Reveals Infrequent Exposure to Statins and Diversiform Presentation of the Disease. Frontiers in Immunology, 2022, 13, .	2.2	6
448	Severe digital ischemia as an unrecognized manifestation in patients with antisynthetase autoantibodies: Case series and systematic literature review. Journal of Scleroderma and Related Disorders, 0, , 239719832210908.	1.0	0
449	Myositis-associated Interstitial Lung Disease: Clinical Characteristics and Factors Related to Pulmonary Function Improvement: A Latin-American Multicenter Cohort Study. ReumatologÃa ClÃnica (English Edition), 2022, 18, 293-298.	0.2	0
450	Clinical and pathological features of immune-mediated necrotising myopathies in a single-centre muscle biopsy cohort. BMC Musculoskeletal Disorders, 2022, 23, 425.	0.8	6
451	Severe rhabdomyolysis due to idiopathic inflammatory myopathies, a wary manifestation of a heterogenous pathology. Acta Clinica Belgica, 2022, , 1-5.	0.5	1
452	Associations between anti-mitochondrial antibodies and cardiac involvement in idiopathic inflammatory myopathy patients. Zeitschrift Fur Rheumatologie, 2024, 83, 214-221.	0.5	2
453	Polymyositis as a paraneoplastic syndrome of a patient with primary pulmonary lymphoepithelioma-like carcinoma: a case report and literature review. Journal of Cardiothoracic Surgery, 2022, 17, 120.	0.4	3
454	256th ENMC international workshop: Myositis specific and associated autoantibodies (MSA-ab): Amsterdam, The Netherlands, 8-10 October 2021. Neuromuscular Disorders, 2022, 32, 594-608.	0.3	13
455	The Genetics of Autoimmune Myositis. Frontiers in Immunology, 2022, 13, .	2.2	6
456	Skeletal muscle provides the immunological micro-milieu for specific plasma cells in anti-synthetase syndrome-associated myositis. Acta Neuropathologica, 2022, 144, 353-372.	3.9	19
457	Polimiositis: evoluciÃ³n de 4 aÃ±os y agudizaciÃ³n en 2019, caso masculino en PopayÃ¡n, Cauca. Medicas UIS, 2022, 35, .	0.0	0
458	Phage display of environmental protein toxins and virulence factors reveals the prevalence, persistence, and genetics of antibody responses. Immunity, 2022, 55, 1051-1066.e4.	6.6	13
459	A multianalyte assay for the detection of dermatomyositis-related autoantibodies based on immunoprecipitation combined with immunoblotting. Modern Rheumatology, 2023, 33, 543-548.	0.9	5
460	Inclusion body myositis and associated diseases: an argument for shared immune pathologies. Acta Neuropathologica Communications, 2022, 10, .	2.4	11
461	Anti-MDA5 dermatomyositis after COVID-19 vaccination: a case-based review. Rheumatology International, 2022, 42, 1629-1641.	1.5	25
463	Dysferlinopathy misdiagnosed with juvenile polymyositis in the pre-symptomatic stage of hyperCKemia: a case report and literature review. BMC Medical Genomics, 2022, 15, .	0.7	7
464	Using multi-parametric quantitative MRI to screen for cardiac involvement in patients with idiopathic inflammatory myopathy. Scientific Reports, 2022, 12, .	1.6	3
465	Is it really myositis? Mimics and pitfalls. Best Practice and Research in Clinical Rheumatology, 2022, 36, 101764.	1.4	5

#	Article	IF	Citations
466	Accuracy of power Doppler ultrasonography in the diagnosis and monitoring of idiopathic inflammatory myopathies. Rheumatology, 0, , .	0.9	0
467	Muscle imaging in myositis: MRI, US, and PET. Best Practice and Research in Clinical Rheumatology, 2022, 36, 101765.	1.4	13
468	Successful treatment with tofacitinib for relapse of rapidly progressive interstitial lung disease in anti-melanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis. Modern Rheumatology Case Reports, 2023, 7, 92-95.	0.3	6
469	Analytical and clinical performance of different platforms simultaneously detecting 15 antinuclear antibodies. Journal of Clinical Laboratory Analysis, 0, , .	0.9	1
470	Advances in SLE classification criteria. Journal of Autoimmunity, 2022, 132, 102845.	3.0	11
471	Predictors of Immunogenic Response to the BNT162b2 mRNA COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases Treated with Rituximab. Vaccines, 2022, 10, 901.	2.1	13
472	Reduced Bone Mineral Density in Patients with Idiopathic Inflammatory Myopathies: A Cross-Sectional Comparative Study. SSRN Electronic Journal, 0, , .	0.4	0
473	Peripheral expansion of myeloid derived suppressor cells is related to disease activity and damage accrual in inflammatory myopathies. Rheumatology, 0, , .	0.9	1
474	Relapses of idiopathic inflammatory myopathies after vaccination against COVID-19: a real-life multicenter Italian study. Internal and Emergency Medicine, 2022, 17, 1921-1928.	1.0	8
475	Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases. Frontiers in Medicine, 0, 9, .	1.2	51
476	Impact of dysphagia and its severity on longâ€term survival and swallowing function outcomes in patients with idiopathic inflammatory myopathies other than inclusion body myositis. International Journal of Rheumatic Diseases, 2022, 25, 897-909.	0.9	3
477	Treatment-naÃ¯ve idiopathic inflammatory myopathy: disease evaluation by fluorodeoxyglucose versus pyrophosphate. Egyptian Journal of Radiology and Nuclear Medicine, 2022, 53, .	0.3	0
478	Autoimmune and autoinflammatory diseases with mucocutaneous manifestations: A pediatric rheumatology perspective. International Journal of Dermatology, 2023, 62, 723-736.	0.5	1
479	Cancer associated autoantibodies in idiopathic inflammatory myopathies: A retrospective cohort from a single center in China. Medicina ClÃ¡nica, 2023, 160, 10-16.	0.3	3
480	Autoimmune Idiopathic Inflammatory Myopathies: Pharmacological Differences and Similarities by Type of Myositis and by Sociodemographic Variables. International Journal of Rheumatology, 2022, 2022, 1-11.	0.9	1
481	Performance of the Revised Classification Criteria for Systemic Autoimmune Rheumatic Diseases and Their Overlap Syndromes. Internal Medicine, 2022, 61, 1947-1952.	0.3	2
482	The effectiveness of dapsone as refracterial therapy for juvenile dermatomyositis. International Journal of Research in Dermatology, 0, , .	0.0	0
483	Physical exercise for dermatomyositis and polymyositis: a systematic review and meta-analysis. Clinical Rheumatology, 2022, 41, 2635-2646.	1.0	2

#	Article	IF	Citations
484	Anti-MDA5 Amyopathic Dermatomyositisâ€"A Diagnostic and Therapeutic Challenge. Life, 2022, 12, 1108.	1.1	3
485	Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis Complicated by Neurological Involvement in a Patient with Dermatomyositis: a Case Report and Literature Review. Modern Rheumatology Case Reports, 0, , .	0.3	0
487	Inflammatory myopathies: an update for neurologists. Arquivos De Neuro-Psiquiatria, 2022, 80, 238-248.	0.3	1
488	Profile of specific and associated autoantibodies in patients with idiopathic inflammatory myopathies in a Colombian population. Frontiers in Medicine, 0, 9, .	1.2	1
489	A Retrospective Analysis of Outcome in Melanoma Differentiationâ€"Associated Gene 5â€"Related Interstitial Lung Disease Treated with Tofacitinib or Tacrolimus. Journal of Rheumatology, 2022, 49, 1356-1364.	1.0	18
490	Concurrence of leukocyte chemotactic factor 2-associated amyloidosis and autoimmune diseases: A case report. Frontiers in Immunology, 0, 13, .	2.2	0
491	Anti-MDA5 Associated Clinically Amyopathic Dermatomyositis With Rapidly Progressive Interstitial Lung Disease. Journal of Medical Cases, 2022, 13, 374-379.	0.4	0
492	An Unusual Cause of Necrotising Fasciitis in a Young Male with Juvenile Dermatomyositis. Case Reports in Rheumatology, 2022, 2022, 1-7.	0.2	0
493	Prevalence of and factors independently associated with digital ischemic complications in patients with systemic sclerosis. Journal of Scleroderma and Related Disorders, 2023, 8, 43-52.	1.0	1
494	Single-cell RNA sequencing to decipher the immunogenicity of ChAdOx1 nCoV-19/AZD1222 and mRNA-1273 vaccines in patients with autoimmune rheumatic diseases. Frontiers in Immunology, 0, 13, .	2.2	1
495	Whole-body MR imaging in evaluation of children with juvenile dermatomyositis. European Journal of Radiology, 2022, 155, 110475.	1.2	4
496	The effect of immunosuppressive therapy on cardiac involvements in antiâ€mitochondrial antibodyâ€positive myositis. ESC Heart Failure, 2022, 9, 4112-4119.	1.4	2
497	Clinical features of anti-mitochondrial M2 antibody-positive myositis: case series of 17 patients. Journal of the Neurological Sciences, 2022, 442, 120391.	0.3	3
498	Dermatomyositis Triggered by Immune Checkpoint Inhibitors. Three Additional Cases and a Review of the Literature. SSRN Electronic Journal, 0, , .	0.4	0
500	Features of MRI honeycomb edema signals in cancer-associated dermatomyositis patients: a brief report. Clinical Rheumatology, 0, , .	1.0	0
501	Bibliometric and altmetric analyses of publication activity in the field of idiopathic inflammatory myopathy in 2011â€"2021 based on web of science core collection databases. Rheumatology International, 2023, 43, 1121-1133.	1.5	4
502	Two clusters of systemic lupus erythematosus patients with muscle involvement in a Chinese cohort. International Journal of Rheumatic Diseases, 2023, 26, 51-59.	0.9	1
503	Subclinical systolic and diastolic myocardial dysfunction in polyphasic polymyositis/dermatomyositis: a 2-year longitudinal study. Arthritis Research and Therapy, 2022, 24, .	1.6	2

#	Article	IF	Citations
504	Long-term risks of malignancy in myositis-specific antibody-positive idiopathic inflammatory myopathy. Rheumatology International, 2023, 43, 335-343.	1.5	2
505	Autoantibodies in the pathogenesis of idiopathic inflammatory myopathies: Does the endoplasmic reticulum stress response have a role?. Frontiers in Immunology, 0, 13, .	2.2	5
507	SIGLEC-1 in Systemic Sclerosis: A Useful Biomarker for Differential Diagnosis. Pharmaceuticals, 2022, 15, 1198.	1.7	10
508	Heliotrope Rash, Gottron Papules and Ragged Cuticles in Darker Skin. American Journal of Medicine, 2022, , .	0.6	0
509	Myostatin in idiopathic inflammatory myopathies: Serum assessment and disease activity. Neuropathology and Applied Neurobiology, 2023, 49, .	1.8	1
510	Immunogenicity decay and case incidence six months post Sinovac-CoronaVac vaccine in autoimmune rheumatic diseases patients. Nature Communications, 2022, 13, .	5.8	3
511	The clinical features of juvenile dermatomyositis: A single-centre inception cohort. Seminars in Arthritis and Rheumatism, 2022, 57, 152104.	1.6	6
512	V. Recent Advances in Understanding Inflammatory Myopathy. The Journal of the Japanese Society of Internal Medicine, 2021, 110, 2189-2195.	0.0	0
513	A case of <scp>Antiâ€MDA5â€Positive</scp> dermatomyositis after inactivated COVIDâ€19 vaccine. Journal of the European Academy of Dermatology and Venereology, 2023, 37, .	1.3	5
514	Interstitial Pneumonia with Autoimmune Features (IPAF): time to redefine the classification criteria. Expert Review of Clinical Immunology, 2023, 19, 131-133.	1.3	3
515	Impaired muscle strength is associated with ultrastructure damage in myositis. Scientific Reports, 2022, 12, .	1.6	0
516	Performance of the 2017 EULAR/ACR criteria for idiopathic inflammatory myopathies in a cohort of patients from Latin America. Medicine (United States), 2022, 101, e31015.	0.4	0
517	Single-cell profiling reveals distinct adaptive immune hallmarks in MDA5+ dermatomyositis with therapeutic implications. Nature Communications, 2022, 13, .	5.8	23
518	B-cell receptor profiling before and after IVIG monotherapy in newly diagnosed idiopathic inflammatory myopathies. Rheumatology, 2023, 62, 2585-2593.	0.9	2
519	A metaâ€analysis of methotrexate polyglutamates in relation to efficacy and toxicity of methotrexate in inflammatory arthritis, colitis and dermatitis. British Journal of Clinical Pharmacology, 2023, 89, 61-79.	1.1	12
520	Relevance of leukemia inhibitory factor to anti-melanoma differentiation-associated gene 5 antibody-positive interstitial lung disease. Rheumatology, 0, , .	0.9	0
521	An observational study of clinical recurrence in patients with interstitial lung disease related to the antisynthetase syndrome. Clinical Rheumatology, 0, , .	1.0	1
522	A case series of dermatomyositis following SARS-CoV-2 vaccination. Frontiers in Medicine, 0, 9, .	1.2	5

#	Article	IF	Citations
523	Circulating VEGF-A, TNF-Î±, CCL2, IL-6, and IFN-Î³ as biomarkers of cancer in cancer-associated anti-TIF1-Î³ antibody-positive dermatomyositis. Clinical Rheumatology, 2023, 42, 817-830.	1.0	3
524	Assessment of Thigh MRI Radiomics and Clinical Characteristics for Assisting in Discrimination of Juvenile Dermatomyositis. Journal of Clinical Medicine, 2022, 11, 6712.	1.0	2
525	Clinical manifestations, outcomes, and antibody profile of Brazilian adult patients with dermatomyositis: a single-center longitudinal study. Advances in Rheumatology, 2022, 62, .	0.8	3
526	Severity of COVID-19 in Patients with Dermatomyositis: A Single Center, Retrospective Observational Cohort Study. SKIN the Journal of Cutaneous Medicine, 2022, 6, 497-501.	0.1	0
528	Assessment of idiopathic inflammatory myopathy using a deep learning method for muscle T2 mapping segmentation. European Radiology, 2023, 33, 2350-2357.	2.3	8
529	The role of bDMARDs in idiopathic inflammatory myopathies: A systematic literature review. Autoimmunity Reviews, 2023, 22, 103264.	2.5	2
530	Dermatomiose Juvenil: Relato De Caso. , 2022, 1, e013.		0
531	Clinical and Radiological Features of Interstitial Lung Diseases Associated with Polymyositis and Dermatomyositis. Medicina (Lithuania), 2022, 58, 1757.	0.8	4
532	Overlap syndrome involving anti-OJ antibody-positive polymyositis, systemic lupus erythematosus and SjÃ¶grenâ€™s syndrome: A case report and literature review. Modern Rheumatology Case Reports, 0, , .	0.3	1
533	Hepatic veno-occlusive disease accompanied by thrombotic microangiopathy developed during treatment of juvenile dermatomyositis and macrophage activation syndrome: A case report. Modern Rheumatology Case Reports, 0, , .	0.3	2
534	Coexistence of Multiple Myositis-Specific Antibodies in Patients with Idiopathic Inflammatory Myopathies. Journal of Clinical Medicine, 2022, 11, 6972.	1.0	0
535	Efficacy and safety of rituximab treatment in patients with idiopathic inflammatory myopathies: A systematic review and meta-analysis. Frontiers in Immunology, 0, 13, .	2.2	8
536	Comparison of cytokine/chemokine profiles between dermatomyositis and anti-synthetase syndrome. Frontiers in Neurology, 0, 13, .	1.1	2
537	MYOSITIS WITH PROMINENT B CELL AGGREGATES MAY MEET CLASSIFICATION CRITERIA FOR SPORADIC INCLUSION BODY MYOSITIS. Neuromuscular Disorders, 2022, , .	0.3	0
538	Co-VAN study: COVID-19 vaccine associated neurological diseases- an experience from an apex neurosciences centre and review of the literature. Journal of Clinical Neuroscience, 2023, 108, 37-75.	0.8	4
539	Immune-Mediated Diseases Following COVID-19 Vaccination: Report of a Teaching Hospital-Based Case-Series. Journal of Clinical Medicine, 2022, 11, 7484.	1.0	6
540	Multiparametric autoantibody analysis: a new paradigm for the diagnosis of connective tissue diseases. Arthritis Research and Therapy, 2022, 24, .	1.6	5
541	Infection Risk in Patients with Dermatomyositis Associated with Anti-MDA5 Antibodies: A Historical Cohort Study. Biomedicines, 2022, 10, 3176.	1.4	2

#	Article	IF	Citations
542	Proteomics Analysis of Plasma-Derived Exosomes Unveils the Aberrant Complement and Coagulation Cascades in Dermatomyositis/Polymyositis. Journal of Proteome Research, 2023, 22, 123-137.	1.8	4
543	Mass spectrometry-based identification of new anti-Ly and known antisynthetase autoantibodies. Annals of the Rheumatic Diseases, 2023, 82, 546-555.	0.5	8
544	Enhanced Activity of NLRP3 Inflammasome in the Lung of Patients with Anti-Synthetase Syndrome. Cells, 2023, 12, 60.	1.8	3
545	Pain in autoimmune inflammatory myopathies: a scoping review. RMD Open, 2023, 9, e002591.	1.8	3
546	Endothelin-1 as a Biomarker of Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Associated with Autoimmune Diseases. International Journal of Molecular Sciences, 2023, 24, 1275.	1.8	8
547	Deciphering the Autoantibody Response to the OJ Antigenic Complex. Diagnostics, 2023, 13, 156.	1.3	1
548	Clinical features and outcomes of patients with myositis associated-interstitial lung disease. Frontiers in Medicine, 0, 9, .	1.2	6
549	Cancer associated autoantibodies in idiopathic inflammatory myopathies: A retrospective cohort from a single center in China. Medicina ClÃnica (English Edition), 2023, 160, 10-16.	0.1	1
550	Clinical Characteristics and Associated Factors for Infection and in-Hospital Mortality in Inpatients with Polymyositis/Dermatomyositis in China: A Retrospective Study. Infection and Drug Resistance, 0, Volume 16, 289-299.	1.1	2
551	Dysphonia in Polymyositis/Dermatomyositis in Adults. Indian Journal of Otolaryngology and Head and Neck Surgery, 0, , .	0.3	0
552	Human epididymis protein 4 as a clinical biomarker in identifying interstitial lung disease in patients with idiopathic inflammatory myopathies. International Immunopharmacology, 2023, 115, 109609.	1.7	0
553	Kollagenosen â€“ Begutachtung. Springer Reference Medizin, 2023, , 1-4.	0.0	0
554	Dermatomyositis Associated with Lung Cancer: A Brief Review of the Current Literature and Retrospective Single Institution Experience. Life, 2023, 13, 40.	1.1	3
555	Scleromyositis: A distinct novel entity within the systemic sclerosis and autoimmune myositis spectrum. Implications for care and pathogenesis. Frontiers in Immunology, 0, 13, .	2.2	11
556	A case of antisynthetase syndrome presenting solely with life-threatening interstitial lung disease. Clinical Medicine, 2023, 23, 85-87.	0.8	2
557	Real-world impact of antifibrotics on prognosis in patients with progressive fibrosing interstitial lung disease. RMD Open, 2023, 9, e002667.	1.8	3
558	Urine proteomics by mass spectrometry identifies proteins involved in key pathogenic pathways in patients with juvenile dermatomyositis. Rheumatology, 2023, 62, 3161-3168.	0.9	3
559	The efficacy and safety of tacrolimus in patients with dermatomyositis/polymyositis: A meta-analysis and systematic review. European Journal of Internal Medicine, 2023, , .	1.0	0

#	Article	IF	Citations
560	Inflammatory myositis-associated interstitial lung disease can be distinguished from that associated with other connective tissue diseases. Journal of Thoracic Disease, 2023, 15, 311-322.	0.6	2
561	Proposal of a new diagnostic algorithm for adult-onset Stillâ€™s disease. Clinical Rheumatology, 2023, 42, 1125-1135.	1.0	4
562	Refractory ventricular tachycardia and heart failure due to anti-mitochondrial antibody-positive inflammatory myopathy. BMC Cardiovascular Disorders, 2023, 23, .	0.7	0
563	Elevated Expression of ADAM10 in Skeletal Muscle of Patients with Idiopathic Inflammatory Myopathies Could Be Responsible for FNDC5/Irisin Unbalance. International Journal of Molecular Sciences, 2023, 24, 2469.	1.8	1
564	Skin manifestations and autoimmune disturbances in dermatomyositis. , 2023, , 437-446.		0
565	Elevation of serum <scp>tenascinâ€C</scp> levels in dermatomyositis patients. International Journal of Rheumatic Diseases, 2023, 26, 1635-1639.	0.9	0
566	Can IgG4-Related Disease present as Isolated myositis?. Neuromuscular Disorders, 2023, , .	0.3	0
567	Subcutaneous tissue involvement in idiopathic inflammatory myopathies: Systematic literature review including three new cases and hypothetical mechanisms. Autoimmunity Reviews, 2023, 22, 103284.	2.5	0
568	Circulating Calprotectin (cCLP) in autoimmune diseases. Autoimmunity Reviews, 2023, 22, 103295.	2.5	14
569	Rapidly progressive interstitial lung disease in clinically amyopathic dermatomyositis triggered by a 23-valent pneumococcal polysaccharide vaccine. Autoimmunity Reviews, 2023, 22, 103307.	2.5	1
571	Fever, Cutaneous Ulcers, and Arthritis Define the MDA5 Phenotype in Indian Patients with Idiopathic Inflammatory Myositis. Mediterranean Journal of Rheumatology, 2022, 33, 413.	0.3	0
572	Peripheral lymphocyte count defines the clinical phenotypes and prognosis in patients with antiâ€MDA5â€positive dermatomyositis. Journal of Internal Medicine, 2023, 293, 494-507.	2.7	8
573	Clinical Outcomes With and Without Plasma Exchange in the Treatment of Rapidly Progressive Interstitial Lung Disease Associated With Idiopathic Inflammatory Myopathy. Journal of Clinical Rheumatology, 2023, 29, 151-158.	0.5	1
574	High prevalence and mortality of Pneumocystis jirovecii pneumonia in anti-MDA5 antibody-positive dermatomyositis. Rheumatology, 2023, 62, 3302-3309.	0.9	4
575	Anti-RuvBL1/2 Autoantibodies Detection in a Patient with Overlap Systemic Sclerosis and Polymyositis. Antibodies, 2023, 12, 13.	1.2	0
576	Diagnosis and Management of Myositis-Associated Lung Disease. Chest, 2023, 163, 1476-1491.	0.4	10
577	Myositis autoantibodies detected by line blot immunoassay: clinical associations and correlation with antibody signal intensity. Rheumatology International, 2023, 43, 1101-1109.	1.5	2
579	The von Willebrand Factor Antigen Reflects the Juvenile Dermatomyositis Disease Activity Score. Biomedicines, 2023, 11, 552.	1.4	7

#	Article	IF	Citations
580	Serum Rcn3 level is a potential diagnostic biomarker for connective tissue disease-associated interstitial lung disease and reflects the severity of pulmonary function. BMC Pulmonary Medicine, 2023, 23, .	0.8	0
581	Clinical Characteristics of Dermatomyositis with Interstitial Lung Disease: A Retrospective Caseâ€“Control Study. Rheumatology and Therapy, 2023, 10, 635-648.	1.1	2
582	Development of Autoantibodies Following BNT162b2 mRNA COVID-19 Vaccination and Their Association with Disease Flares in Adult Patients with Autoimmune Inflammatory Rheumatic Diseases (AIIRD) and the General Population: Results of 1-Year Prospective Follow-Up Study. Vaccines, 2023, 11, 476.	2.1	6
583	Classification of Immune-Mediated Myopathies. , 2023, , 21-35.		0
584	Specific Forms of Immune-Mediated Necrotizing Myopathies. , 2023, , 73-100.		0
585	Idiopathic Inflammatory Myopathies. , 2023, , 37-72.		0
586	Current Concepts and Future Prospects in Immune-Mediated Myopathies. , 2023, , 161-189.		0
587	Myositis-Specific and Myositis-Associated Antibodies in Fibromyalgia Patients: A Prospective Study. Biomedicines, 2023, 11, 658.	1.4	0
588	The diagnostic value of urinary N-terminal fragment of titin for skeletal muscle damage in idiopathic inflammatory myopathy. Rheumatology, 0, , .	0.9	0
589	Clinical and Radiological Features of Korean Patients With Anti-HMGCR Myopathy. Journal of Clinical		

#	Article	IF	Citations
598	Safety and Immunogenicity Following the Second and Third Doses of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents with Juvenile-Onset Autoimmune Inflammatory Rheumatic Diseases: A Prospective Multicentre Study. Vaccines, 2023, 11, 819.	2.1	0
599	In-depth proteomic analysis of juvenile dermatomyositis serum reveals protein expression associated with muscle-specific autoantibodies. Rheumatology, 0, , .	0.9	0
600	Rapidly progressive respiratory failure due to antisynthetase syndrome related interstitial lung disease. Respirology Case Reports, 2023, 11, .	0.3	0
601	Clinical significance of anti-NT5c1A autoantibody in Korean patients with inflammatory myopathies. PLoS ONE, 2023, 18, e0284409.	1.1	2
602	Case 12-2023: A 44-Year-Old Woman with Muscle Weakness and Myalgia. New England Journal of Medicine, 2023, 388, 1513-1520.	13.9	0
603	Semi-quantitative thigh magnetic resonance imaging scores in assessing disease activity and determining long-term clinical outcome in idiopathic inflammatory myopathies: a causal mediation analysis. Rheumatology, 2024, 63, 111-118.	0.9	0
608	Case report: Unusual patient with dermatomyositis associated with SARS-CoV-2 infection. Frontiers in Neurology, 0, 14, .	1.1	1
665	Nontuberculous mycobacterial myositis in dermatomyositis with long-term use of immunosuppressant: a case report. Skeletal Radiology, 0, , .	1.2	0
670	Wenn jede Bewegung und auch das Lachen zur Qual wird. , 2023, , 109-120.		0
671	Idiopathic Inflammatory Myopathies. , 2023, , 1-18.		0
673	Successful management of interstitial lung disease in dermatomyositis complicated by malignancy: a case-based review. Rheumatology International, 0, , .	1.5	0
676	EntzÃ¼ndliche Myopathien. , 2023, , 175-192.		0
696	Idiopathic Inflammatory Myopathies. Indian Journal of Pediatrics, 0, , .	0.3	1
706	Anti-MDA5 antibody-positive dermatomyositis: pathogenesis and clinical progress. Nature Reviews Rheumatology, 0, , .	3.5	1
712	Immune checkpoint inhibitor-related myositis and myocarditis: diagnostic pitfalls and imaging contribution in a real-world, institutional case series. Journal of Neurology, 0, , .	1.8	0
717	Complement and MHC patterns can provide the diagnostic framework for inflammatory neuromuscular diseases. Acta Neuropathologica, 2024, 147, .	3.9	1